<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cell Biol</journal-id><journal-title>BMC Cell Biology</journal-title><issn pub-type="epub">1471-2121</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2121-8-34</article-id><article-id pub-id-type="pmid">17697341</article-id><article-id pub-id-type="doi">10.1186/1471-2121-8-34</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>GSK-3 inhibitors induce chromosome instability</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Tighe</surname><given-names>Anthony</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>anthony.tighe@manchester.ac.uk</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Ray-Sinha</surname><given-names>Arpita</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>arpitaray@hotmail.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Staples</surname><given-names>Oliver D</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>O.D.Staples@dundee.ac.uk</email></contrib><contrib id="A4" corresp="yes" contrib-type="author"><name><surname>Taylor</surname><given-names>Stephen S</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>stephen.taylor@manchester.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>Faculty of Life Sciences, Michael Smith Building, Oxford Road, University of Manchester, Manchester M13 9PT, UK</aff><aff id="I2"><label>2</label>Division of Surgery and Oncology, University of Liverpool, 5<sup>th </sup>Floor UCD Building, Daulby Street, Liverpool, L69 3GA, UK</aff><aff id="I3"><label>3</label>Department of Surgery and Molecular Oncology, Ninewells Hospital, University of Dundee, Dundee DD1 9SY, UK</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>14</day><month>8</month><year>2007</year></pub-date><volume>8</volume><fpage>34</fpage><lpage>34</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2121/8/34"/><history><date date-type="received"><day>2</day><month>2</month><year>2007</year></date><date date-type="accepted"><day>14</day><month>8</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Tighe et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Tighe et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Tighe Anthony anthony.tighe@manchester.ac.uk </dc:author><dc:title> GSK-3 inhibitors induce chromosome instability </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Cell Biology 8(1): 34-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2121(2007)8:1&#x0003c;34&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2121</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Several mechanisms operate during mitosis to ensure accurate chromosome segregation. However, during tumour evolution these mechanisms go awry resulting in chromosome instability. While several lines of evidence suggest that mutations in <italic>adenomatous polyposis coli </italic>(<italic>APC</italic>) may promote chromosome instability, at least in colon cancer, the underlying mechanisms remain unclear. Here, we turn our attention to GSK-3 &#x02013; a protein kinase, which in concert with APC, targets &#x003b2;-catenin for proteolysis &#x02013; and ask whether GSK-3 is required for accurate chromosome segregation.</p></sec><sec><title>Results</title><p>To probe the role of GSK-3 in mitosis, we inhibited GSK-3 kinase activity in cells using a panel of small molecule inhibitors, including SB-415286, AR-A014418, 1-Azakenpaullone and CHIR99021. Analysis of synchronised HeLa cells shows that GSK-3 inhibitors do not prevent G1/S progression or cell division. They do, however, significantly delay mitotic exit, largely because inhibitor-treated cells have difficulty aligning all their chromosomes. Although bipolar spindles form and the majority of chromosomes biorient, one or more chromosomes often remain mono-oriented near the spindle poles. Despite a prolonged mitotic delay, anaphase frequently initiates without the last chromosome aligning, resulting in chromosome non-disjunction. To rule out the possibility of "off-target" effects, we also used RNA interference to selectively repress GSK-3&#x003b2;. Cells deficient for GSK-3&#x003b2; exhibit a similar chromosome alignment defect, with chromosomes clustered near the spindle poles. GSK-3&#x003b2; repression also results in cells accumulating micronuclei, a hallmark of chromosome missegregation.</p></sec><sec><title>Conclusion</title><p>Thus, not only do our observations indicate a role for GSK-3 in accurate chromosome segregation, but they also raise the possibility that, if used as therapeutic agents, GSK-3 inhibitors may induce unwanted side effects by inducing chromosome instability.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Genome stability requires that the replicated chromosomes are accurately segregated during mitosis [<xref ref-type="bibr" rid="B1">1</xref>]. Chromosome segregation is mediated by a microtubule spindle, to which chromosomes attach via their kinetochores, complex microtubule-binding structures which assemble at the centromeric heterochromatin [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. Kinetochores not only attach chromosomes to the spindle, they also perform two key functions which maintain chromosome stability. Firstly, by undergoing rounds of microtubule capture-and-release, kinetochores select microtubule attachments which yield tension across the centromere [<xref ref-type="bibr" rid="B5">5</xref>]. This in turn promotes chromosome biorientation, i.e. sister kinetochores attached to opposite spindle poles. Secondly, by monitoring microtubule occupancy and/or tension, kinetochores regulate the spindle checkpoint, a surveillance mechanism which delays anaphase until all the chromosomes are bioriented [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>As a consequence of these mechanisms, most normal proliferating human cells are diploid and karyotypically stable. By contrast, many tumour cells exhibit chromosome instability and are therefore karyotypically unstable and aneuploid [<xref ref-type="bibr" rid="B7">7</xref>]. Much effort has gone into defining the genetic lesions responsible for the chromosome instability and recently, <italic>adenomatous polyposis coli </italic>(<italic>APC</italic>) has emerged as a candidate, at least in colon cancer [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. APC is best known for its role in the Wnt signalling pathway: in the absence of Wnt signals, a destruction complex of APC and axin recruits both &#x003b2;-catenin and GSK-3 [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Phosphorylation of &#x003b2;-catenin by GSK-3&#x003b2; then targets &#x003b2;-catenin for proteolysis. In the presence of Wnt signals, &#x003b2;-catenin phosphorylation is inhibited, resulting in the upregulation of proliferative genes. This mechanism is essential for tumour suppressor function in the colonic epithelia: almost all colon cancers have either loss of function mutations in APC or activating mutations in &#x003b2;-catenin [<xref ref-type="bibr" rid="B12">12</xref>]. However, APC is a large multi-domain protein and its function is not restricted to the Wnt pathway.</p><p>Evidence is mounting that APC is somehow required for the fidelity of chromosome segregation. APC is a microtubule binding protein and has the ability to stabilise plus ends [<xref ref-type="bibr" rid="B13">13</xref>]. In mitosis, APC localises to kinetochores in a microtubule dependent manner [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>], and tumour cells with APC mutations have weaker kinetochore &#x02013; microtubule interactions [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. Spindles assembled in <italic>Xenopus </italic>egg extracts depleted of APC are abnormal [<xref ref-type="bibr" rid="B18">18</xref>]. APC also localises to centrosomes [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B21">21</xref>], and in the <italic>Drosophila </italic>germ line, APC is required for spindle positioning [<xref ref-type="bibr" rid="B22">22</xref>]. In mice, APC mutation enhances genomic instability and tumour formation in cells haploinsufficient for BubR1, a spindle checkpoint kinase [<xref ref-type="bibr" rid="B23">23</xref>]. Murine embryonic stem cells with APC mutations are frequently tetraploid [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. Ectopic expression of N-terminal APC mutants in diploid, APC-proficient human cells compromises the spindle checkpoint and enhances survival following prolonged mitotic arrest, leading to aneuploidy [<xref ref-type="bibr" rid="B21">21</xref>]. However, despite this body of evidence, the molecular mechanisms linking APC and chromosome instability remain unclear.</p><p>One possibility is that APC mutation compromises EB1, a microtubule tip-tracking protein involved in microtubule dynamics, spindle positioning, chromosome stability and cytokinesis [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. EB1 binds the C-terminus of APC [<xref ref-type="bibr" rid="B26">26</xref>], so it is conceivable that the binding of N-terminal APC mutants to partners, including full length APC, excludes EB1 from complexes required for microtubule processes [<xref ref-type="bibr" rid="B17">17</xref>]. Another possible mechanism lies with, GSK-3. Like APC, the function of GSK-3 is not restricted to the Wnt pathway, rather it has been implicated in a plethora of processes including glycogen metabolism and tau phosphorylation [<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B29">29</xref>], and more recently, regulating kinesin-driven organelle movement [<xref ref-type="bibr" rid="B30">30</xref>] and Cyclin E degradation [<xref ref-type="bibr" rid="B31">31</xref>]. Importantly, GSK-3 has been implicated in regulating interphase microtubule dynamics [<xref ref-type="bibr" rid="B32">32</xref>]. Phosphorylated GSK-3 localises to spindle poles in mitosis [<xref ref-type="bibr" rid="B33">33</xref>]. In both budding and fission yeast, overexpression of GSK-3 suppresses mutations in kinetochore proteins and the centromeric DNA [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>]. Interestingly, Bub1 and BubR1, two related protein kinases which localise to kinetochores and are required for spindle checkpoint function [<xref ref-type="bibr" rid="B36">36</xref>], phosphorylate APC <italic>in vitro </italic>[<xref ref-type="bibr" rid="B15">15</xref>]. While the significance of this is unclear, phosphorylation is enhanced if APC is already phosphorylated by GSK-3 [<xref ref-type="bibr" rid="B15">15</xref>]. In one study, small molecule GSK-3 inhibitors were shown to induce spindle defects and chromosome misalignment [<xref ref-type="bibr" rid="B33">33</xref>]. However, whether these chromosomes eventually aligned before anaphase onset is unclear. Indeed, we envision two possible scenarios; either the chromosomes never align, yielding prolonged checkpoint arrest followed by adaptation and mitotic exit without dividing, yielding tetraploid cells [<xref ref-type="bibr" rid="B37">37</xref>]; or alternatively, the spindle checkpoint "gives up" and the cells enter anaphase despite unaligned chromosomes, thereby missegregating only those chromosomes [<xref ref-type="bibr" rid="B38">38</xref>].</p><p>To distinguish between these possibilities and further probe the role of GSK-3 in mitotic chromosome segregation, we characterised a panel of structurally diverse GSK-3 inhibitors. We show that these inhibitors have profound effects on cell cycle control, spindle morphology and chromosome alignment. Strikingly, these inhibitors increase the frequency with which cells missegregate their chromosomes. In support of the notion that these phenotypes are due to inhibition of GSK-3, rather than off target effects, we use RNA interference to selectively repress GSK-3&#x003b2;. This results in a chromosome alignment defect and the formation of micronuclei, a hallmark of chromosome missegregation.</p></sec><sec><title>Results</title><sec><title>Characterisation of small molecule GSK-3 inhibitors</title><p>A number of small molecules have been identified which inhibit GSK-3 <italic>in vitro </italic>[<xref ref-type="bibr" rid="B27">27</xref>]. To determine whether GSK-3 is required for accurate chromosome segregation, we obtained a panel of structurally diverse inhibitors (Fig. <xref ref-type="fig" rid="F1">1</xref> and Table <xref ref-type="table" rid="T1">1</xref>) and tested their ability to inhibit glycogen synthase (GS) phosphorylation in cells [<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref>]. As a negative control, we used DMSO, the solvent in which the drugs were dissolved, and as a positive control we used lithium chloride, a well established GSK-3 inhibitor [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B42">42</xref>]. When HeLa cells were treated with GSK-3 inhibitors for 24 hours, only SB-415286, AR-A014418, 1-Azakenpaullone, CHIR99021 and Inhibitor XI significantly reduced GS phosphorylation (Fig. <xref ref-type="fig" rid="F2">2A</xref>). TDZD-8, Inhibitor II and OTDZT had little effect (Fig. <xref ref-type="fig" rid="F2">2A</xref>), even when used at relatively high concentrations (not shown).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>GSK-3 inhibitors used in this study</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Compound</bold></td><td align="center"><bold>Class</bold></td><td align="center"><bold>Mechanism</bold></td><td align="center"><bold>In vitro IC<sub>50</sub></bold></td><td align="center"><bold>Conc. used in cells</bold></td><td align="center"><bold>Ref.</bold></td></tr></thead><tbody><tr><td align="center">SB-415286</td><td align="center">Arylindole-maleimides</td><td align="center">ATP Competitor</td><td align="center">78 nM</td><td align="center">30 &#x003bc;M</td><td align="center">[44]</td></tr><tr><td align="center">AR-A014418</td><td align="center">Thiazole</td><td align="center">ATP Competitor</td><td align="center">104 nM</td><td align="center">20 &#x003bc;M</td><td align="center">[58]</td></tr><tr><td align="center">1-Aza kenpaullone</td><td align="center">Benzazepinone</td><td align="center">ATP Competitor</td><td align="center">18 nM</td><td align="center">2.5 &#x003bc;M</td><td align="center">[57]</td></tr><tr><td align="center">CHIR99021</td><td align="center">Aminopyrimidine</td><td align="center">ATP Competitor</td><td align="center">7 nM</td><td align="center">10 &#x003bc;M</td><td align="center">[47]</td></tr><tr><td align="center">Lithium</td><td align="center">Divalent ion</td><td align="center">Non competitive</td><td align="center">2 mM</td><td align="center">40 mM</td><td align="center">[41]</td></tr><tr><td align="center">TDZD-8</td><td align="center">Thiadiazolidinone</td><td align="center">Non competitive</td><td align="center">2 &#x003bc;M</td><td align="center">10&#x02013;60 &#x003bc;M</td><td align="center">[70]</td></tr><tr><td align="center">Inhibitor II</td><td align="center">Pyridyloxadiazole</td><td align="center">-</td><td align="center">390 nM</td><td align="center">25&#x02013;75 &#x003bc;M</td><td align="center">[71]</td></tr><tr><td align="center">OTDZT</td><td align="center">Thiadiazolidinone</td><td align="center">Non competitive</td><td align="center">10 &#x003bc;M</td><td align="center">50&#x02013;100 &#x003bc;M</td><td align="center">[70]</td></tr><tr><td align="center">Inhibitor XI</td><td align="center">Azaindolylmaleimide</td><td align="center">ATP Competitor</td><td align="center">32 nM</td><td align="center">50 &#x003bc;M</td><td align="center">[72]</td></tr></tbody></table></table-wrap><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Small molecule inhibitors of GSK-3</bold>. Chemical structures of SB-415286, 1-Azakenpaullone, AR-A014418 and CHIR99021</p></caption><graphic xlink:href="1471-2121-8-34-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Identification of small molecules which inhibit GSK-3 <italic>in vivo</italic></bold>. HeLa and DLD-1 cells were incubated with small molecule GSK-3 inhibitors for 24 hours then analysed by immunoblotting and immunofluorescence. (<bold>A</bold>) Immunoblot of HeLa cell extracts showing inhibition of glycogen synthase phosphorylation by a subset of GSK-3 inhibitors. (B) Immunoblot of HeLa cell extracts showing that GSK-3 inhibitors do not inhibit Cdk1 phosphorylation of nucleolin. (<bold>C</bold>) Images of mitotic DLD-1 cells showing examples of abnormal metaphase spindles following exposure to AR-A014418 and 1-Azakenpaullone. (<bold>D</bold>) Bar graph plotting the number of abnormal metaphases in cells treated with different small molecule GSK-3 inhibitors.</p></caption><graphic xlink:href="1471-2121-8-34-2"/></fig><p>Several GSK-3 inhibitors have been shown to inhibit members of the CDK family, at least <italic>in vitro </italic>[<xref ref-type="bibr" rid="B27">27</xref>]. We therefore asked whether cellular Cdk1 activity was inhibited by the GSK-3 inhibitors used here. HeLa cells were synchronised in mitosis with nocodazole then exposed to GSK-3 inhibitors. In parallel, cells were exposed to a <italic>bone fide </italic>Cdk1 inhibitor, RO-31-8220 [<xref ref-type="bibr" rid="B43">43</xref>]. To prevent mitotic exit, the proteasome inhibitor MG132 was also added to the cells. Cell lysates were then prepared and immunoblotted for phospho-nucleolin, a known Cdk1 substrate (Fig. <xref ref-type="fig" rid="F2">2B</xref>). While RO-31-8220 clearly inhibited the phosphorylation of nucleolin, the GSK-3 inhibitors had no apparent effect. Thus, at the concentrations where GSK-3 is clearly inhibited (Fig. <xref ref-type="fig" rid="F2">2A</xref>), there does not appear to be any appreciable inhibition of Cdk1.</p><p>Next, we analysed spindle morphology in drug-treated mitotic DLD-1 cells. In controls, or cells treated with compounds which did not inhibit GS phosphorylation, normal metaphase spindles were readily apparent (Fig. <xref ref-type="fig" rid="F2">2C</xref>). By contrast, cells treated with compounds which did inhibit GS phosphorylation, frequently exhibited abnormal chromosome configurations. Specifically, although bipolar spindles formed and most chromosomes aligned at the metaphase plate, some chromosomes were often clustered near the spindle poles (Fig. <xref ref-type="fig" rid="F2">2C</xref>). For example, in the presence of the highly specific GSK-3 inhibitor, CHIR99021, ~49% of metaphases had one or more chromosomes clustered near the spindle poles (Fig. <xref ref-type="fig" rid="F2">2D</xref>). Thus, five structurally diverse small molecules which inhibit GSK-3 activity in cells induced a chromosome alignment defect.</p></sec><sec><title>GSK-3 inhibitors delay mitotic entry and exit</title><p>Although GSK-3 inhibitors have been used extensively to study insulin action [<xref ref-type="bibr" rid="B44">44</xref>-<xref ref-type="bibr" rid="B47">47</xref>], very little is know about their effects on the cell cycle. In light of the observation described above, we therefore analysed the effect of GSK-3 inhibitors on cell cycle progression. HeLa cells were synchronised in early S-phase using a double thymidine block then released into drug free media, or media supplemented with SB-415286 or nocodazole. Over the next 24 hours cells were harvested at regular intervals and analysed by flow cytometry to determine DNA content and mitotic index. Control cells progressed through S-phase then entered mitosis 9 hours after release (Fig. <xref ref-type="fig" rid="F3">3A, B</xref>). The mitotic index peaked at ~20% 10 hours post-release then, as division was completed, cells with 2N DNA contents reappeared. 17 hours post-release, i.e. 5&#x02013;6 hours after returning to G1, these cells entered a second S-phase. Cells released into nocodazole completed S-phase but then, consistent with hyper-activation of the spindle checkpoint, arrested in mitosis maintaining 4N DNA contents. Cells released into SB-415286 also progressed through the first S-phase will normal kinetics (Fig. <xref ref-type="fig" rid="F3">3A</xref>) but the mitotic index did not increase until 13 hours post-release, indicating a mitotic entry delay of ~3 hours (Fig. <xref ref-type="fig" rid="F3">3B</xref>). 17 hours post-release, the mitotic index peaked at ~30%. After this, the number of cells with 2N DNA contents started to increase, indicating successful cell division. By 23 hours, i.e. ~6 hours after they returned to G1, SB-415286-treated cells entered a second S phase. Thus in HeLa cells, SB-415286 has no apparent effect on G1/S progression and neither does it prevent cell division. SB-415286 does however delay mitotic entry and mitotic exit.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>GSK-3 inhibitors delay mitotic entry and exit</bold>. HeLa cells were synchronised at G1/S then released into drug-free medium or medium containing either SB-415286 or nocodazole. At the time points indicated the cells, were harvested and analysed by flow cytometry to determine DNA content and mitotic index. (<bold>A</bold>) DNA content histograms showing that SB-415286 delays cell division. (<bold>B</bold>) Graph plotting the mitotic index, as determined by MPM-2 reactivity, showing that mitotic progression is delayed in SB-415286 treated cells.</p></caption><graphic xlink:href="1471-2121-8-34-3"/></fig></sec><sec><title>GSK-3 inhibitors delay chromosome alignment</title><p>To determine why SB-415286 delayed mitotic progression, we analysed drug-treated DLD-1 cells by time-lapse microscopy, using a GFP-tagged histone to visualise the chromosomes [<xref ref-type="bibr" rid="B38">38</xref>]. Control cells typically aligned their chromosomes within ~22 minutes (Table <xref ref-type="table" rid="T2">2</xref>) then underwent a normal anaphase (Fig. <xref ref-type="fig" rid="F4">4A</xref>). Note that untreated cells never entered anaphase with unaligned chromosomes (Table <xref ref-type="table" rid="T3">3</xref>). By contrast, chromosome alignment was often delayed in SB-415286 treated cells and anaphase was often initiated with unaligned chromosomes. For example, Figure <xref ref-type="fig" rid="F4">4B</xref> shows two cells, marked <bold><italic>a </italic></bold>and <bold><italic>b</italic></bold>, which, at T = 34 minutes still have unaligned chromosomes (one in <bold><italic>a</italic></bold>, and two in <bold><italic>b</italic></bold>, see arrow head and arrows respectively). At T = 39 minutes, the last chromosome in cell <bold><italic>a </italic></bold>aligns and anaphase initiates at T = 46. By T = 96.5 minutes, one of the laggards in cell <bold><italic>b </italic></bold>has congressed, but one remains unaligned (see asterisk). At T = 100.5, cell <bold><italic>b </italic></bold>enters anaphase, without the last chromosome aligning.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Effect of SB-415286 inhibitors on mitotic timing</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Compound</bold></td><td align="center"><bold>Event</bold></td><td align="center"><bold>Time (mins)</bold></td><td align="center"><bold>s.e.m.</bold></td><td align="center"><bold>Range</bold></td><td align="center"><bold>N</bold></td><td align="center"><bold>P</bold></td></tr></thead><tbody><tr><td align="center">Untreated</td><td align="center">NEB-Metaphase</td><td align="center">21.59</td><td align="center">1.49</td><td align="center">12&#x02013;72</td><td align="center">41</td><td align="center">-</td></tr><tr><td></td><td align="center">Metaphase-Anaphase</td><td align="center">10.65</td><td align="center">0.92</td><td align="center">1.5&#x02013;35.5</td><td align="center">49</td><td align="center">-</td></tr><tr><td align="center">SB-415286</td><td align="center">NEB-Metaphase</td><td align="center">46.04</td><td align="center">4.32</td><td align="center">17.5&#x02013;162</td><td align="center">42</td><td align="center">p &#x0003c; 0.01</td></tr><tr><td></td><td align="center">Metaphase-Anaphase</td><td align="center">11.32</td><td align="center">1.2</td><td align="center">1.5&#x02013;55</td><td align="center">57</td><td align="center">p &#x0003e; 0.05</td></tr></tbody></table><table-wrap-foot><p>Values represent the mean time, in minutes, taken from nuclear envelope breakdown to metaphase and metaphase to anaphase in minutes. Also shown is showing the standard error of the mean, the range and the number of cells analysed. P values determined using a Kruskal-Wallis test.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Effect of GSK-3 inhibitors on mitotic timing and chromosome non-disjunction</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Compound</bold></td><td align="center"><bold>Time (mins)</bold></td><td align="center"><bold>s.e.m.</bold></td><td align="center"><bold>Range</bold></td><td align="center"><bold>N</bold></td><td align="center"><bold>#</bold></td><td align="center"><bold>P</bold></td></tr></thead><tbody><tr><td align="center">-</td><td align="center">25.37</td><td align="center">0.35</td><td align="center">16&#x02013;42</td><td align="center">189</td><td align="center">0</td><td align="center">-</td></tr><tr><td align="center">SB4</td><td align="center">69.56</td><td align="center">3.44</td><td align="center">26&#x02013;214</td><td align="center">99</td><td align="center">15</td><td align="center">p &#x0003c; 0.001</td></tr><tr><td align="center">AR</td><td align="center">92.88</td><td align="center">10.02</td><td align="center">24&#x02013;268</td><td align="center">41</td><td align="center">3</td><td align="center">p &#x0003c; 0.001</td></tr><tr><td align="center">Ken</td><td align="center">31.87</td><td align="center">0.48</td><td align="center">20&#x02013;82</td><td align="center">348</td><td align="center">2</td><td align="center">p &#x0003c; 0.001</td></tr><tr><td align="center">CHIR</td><td align="center">43.94</td><td align="center">1.93</td><td align="center">20&#x02013;214</td><td align="center">187</td><td align="center">8</td><td align="center">p &#x0003c; 0.001</td></tr></tbody></table><table-wrap-foot><p>Values represent the mean time, in minutes, taken from nuclear envelope breakdown to metaphase, Also shown is the standard error of the mean, the range, the number of cells analysed (N), the number of cells which enter anaphase with unaligned chromosomes (#). P values determined using a Kruskal-Wallis test.</p></table-wrap-foot></table-wrap><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>GSK-3 inhibitors delay chromosome alignment</bold>. DLD-1 cells expressing a tagged GFP-Histone H2B were incubated in the presence or absence of small molecule GSK-3 inhibitors then analysed by time-lapse microscopy. (<bold>A</bold>) Control cell showing normal mitosis. (<bold>B</bold>) SB-415286-treated cells. While cell <bold><italic>a </italic></bold>completes mitosis normally, chromosome alignment in cell <bold><italic>b </italic></bold>is delayed (see arrows) and anaphase is initiated despite one unaligned chromosome (see *). (<bold>C</bold>) Box plot measuring time from prophase to metaphase and metaphase to anaphase for at least 42 cells. (<bold>D</bold>) Box plot measuring time taken from nuclear envelope breakdown (NEB) to anaphase onset. Values taken from at least 41 cells.</p></caption><graphic xlink:href="1471-2121-8-34-4"/></fig><p>To quantitate these effects, we measured the time taken from prophase to metaphase, i.e. when the last chromosome aligned, and the time taken from metaphase to anaphase. While control cells took 21.6 &#x000b1; 1.4 minutes to reach metaphase, SB4-treated cells took, on average, 46.0 &#x000b1; 4.3 minutes (Fig. <xref ref-type="fig" rid="F4">4C</xref>, Table <xref ref-type="table" rid="T2">2</xref>). Anaphase initiated ~11 minutes later in both control (10.7 &#x000b1; 0.9 minutes) and SB-415286-treated (11.3 &#x000b1; 1.2 minutes) cells. Importantly however, six out of thirty-two SB-415286 treated cells entered anaphase with one or more unaligned chromosomes. This phenomenon was not restricted to SB-415286. In a separate set of experiments, we measured the time from nuclear envelope breakdown (NEB) to anaphase in the presence of SB-415286, AR-A014418, 1-Azakenpaullone and CHIR99021. Like SB-415286, AR-A014418 induced a prolonged mitotic delay (NEB to anaphase, 92.9 &#x000b1; 4 minutes, Fig. <xref ref-type="fig" rid="F4">4D</xref>, Table <xref ref-type="table" rid="T3">3</xref>). Following chromosome alignment, anaphase initiated with normal kinetics (not shown), confirming that the prolonged mitosis was due to delayed chromosome alignment. 1-Azakenpaullone and CHIR99021 induced modest but never-the-less significant (p &#x0003c; 0.001) delays, (Fig. <xref ref-type="fig" rid="F4">4D</xref>, Table <xref ref-type="table" rid="T3">3</xref>). Importantly, a proportion of the cells exposed to AR-A014418, 1-Azakenpaullone and CHIR99021 entered anaphase with unaligned chromosomes (Table <xref ref-type="table" rid="T3">3</xref>).</p><p>To see if such chromosome missegregation events would lead to aneuploidy, diploid HCT116 cells were exposed SB-415286 for 48 hours, metaphase spreads prepared then chromosome number determined. At day 0, the majority of untreated control cells had a near diploid karyotype, with only 3% of the cells having more than 49 chromosomes (not shown). By contrast, 13.4% of cells treated with SB-415286 had more than 49 chromosomes. By day 5, the aneuploid population (&#x0003e;49 chromosomes) in control cells was 5.6%, however in SB-415286 treated cells, 26.3% were now aneuploid (not shown).</p><p>Thus, when exposed to GSK-3 inhibitors, chromosome alignment is delayed and anaphase is often initiated in the presence of unaligned chromosomes yielding aneuploid cells.</p></sec><sec><title>GSK-3 inhibitors induce mono-orientations</title><p>To determine why complete chromosome alignment was delayed in cells treated with GSK-3 inhibitors, we analysed K-fibres using high-resolution optical sectioning microscopy. To visualise centromeres and kinetochores, we stained cells with anti-centromere antibodies (ACA) and anti-BubR1 antibodies respectively. In control cells, chromosomes near the spindle equator were clearly bioriented: microtubules terminated at BubR1 foci which were connected by ACA staining (Fig. <xref ref-type="fig" rid="F5">5A</xref>). In drug-treated cells, chromosomes near the spindle equator also appeared to be correctly bioriented (Fig. <xref ref-type="fig" rid="F5">5B</xref>). However, chromosomes near the spindle poles were typically mono-oriented, with one kinetochore attached to the nearest spindle pole and the other unattached (Panels <bold><italic>i </italic></bold>in Fig. <xref ref-type="fig" rid="F5">5D, E</xref>). In some cases, microtubules from the same pole could be seen extending towards both kinetochores of an unaligned chromosome, indicating a possible syntelic orientation (Fig. <xref ref-type="fig" rid="F5">5C</xref> and panels <bold><italic>ii </italic></bold>in <xref ref-type="fig" rid="F5">5D, E</xref>). Thus, while GSK-3 inhibitors do not prevent kinetochore biorientation or chromosome congression, they do appear to inhibit the ability of a cell to perfectly biorient all its chromosomes.</p><fig position="float" id="F5"><label>Figure 5</label><caption><p><bold>GSK-3 inhibitors yield monopolar and syntelic attachments</bold>. DLD-1 cells were incubated with GSK-3 inhibitors for 24 hours then fixed and stained to detect DNA (red), tubulin (green), BubR1 (blue) and centromeres (ACA, red) as indicated. Images represent projections of deconvolved image stacks. (<bold>A</bold>) Control cell showing examples of bioriented chromosomes. (<bold>B</bold>) GSK-3 inhibitor treated cell showing that chromosomes near the metaphase plate are bioriented. (<bold>C-E</bold>) Inhibitor treated cells showing examples of either syntelic attachments (C, Dii, Eii) or monopolar attachments (Di, Ei). Bar is 5 &#x003bc;m when the entire spindle is shown or 1 &#x003bc;m in the enlargements. The cells in C-E were treated with 30 &#x003bc;M SB-415286.</p></caption><graphic xlink:href="1471-2121-8-34-5"/></fig></sec><sec><title>GSK-3 inhibitors alter spindle morphology</title><p>During the analysis described above (Figs <xref ref-type="fig" rid="F2">2B</xref> and <xref ref-type="fig" rid="F5">5</xref>), we noticed that in drug-treated cells, spindle morphology appeared abnormal in that there appeared to be increased astral microtubules near the pole around which chromosomes clustered. In addition, spindle length appeared to increase. Examples of both these phenotypes are shown in Figure <xref ref-type="fig" rid="F6">6A</xref>. In panel <bold><italic>i</italic></bold>, the control cell shows a normal spindle morphology, with the chromosomes aligned between two robust crescent-shaped half spindles, and a small number of astral microtubules projecting away from the poles. In panel <bold><italic>ii</italic></bold>, the spindle seems abnormally long, with the half spindles forming cones rather than crescents. In panel <bold><italic>iii</italic></bold>, the pole on the right appears as a radial aster with equal numbers of microtubules pointing in all directions, rather than a crescent oriented towards the spindle equator.</p><fig position="float" id="F6"><label>Figure 6</label><caption><p><bold>GSK-3 inhibitors weaken the spindle midzone</bold>. DLD-1 cells were incubated for 24 hours with GSK-3 inhibitors then fixed and stained to detect the microtubules and the chromosomes. (<bold>A</bold>) Projections of deconvolved image stacks showing representative mitotic spindles. Scale bar: 5 &#x003bc;m. (<bold>B</bold>) Graphs plotting tubulin intensity along the spindle axis. (<bold>C</bold>) Bar graphs plotting pole-pole distance. Values represent the mean and s.e.m. derived from at least 18 cells. (<bold>D</bold>) Bar graphs quantifying the tubulin intensity at the spindle midzone. Values represent the mean and s.e.m. derived from at least 15 cells. The cells in parts A-B were treated with either 2.5 &#x003bc;M 1-Azakenpaullone or 30 &#x003bc;M SB-415286</p></caption><graphic xlink:href="1471-2121-8-34-6"/></fig><p>To quantitate these differences, we measured tubulin fluorescence intensities from one end of the cell to the other along the spindle axis [<xref ref-type="bibr" rid="B48">48</xref>]. When plotted as a function of spindle position, the tubulin intensity typically gave two peaks, corresponding to the spindle poles, and a trough, corresponding to the spindle midzone (Fig. <xref ref-type="fig" rid="F6">6B</xref>). In some cells, the peaks were further apart in drug-treated cells indicating an extended spindle length (Fig. <xref ref-type="fig" rid="F6">6B</xref>, top panel). However, in other cases there appeared to be little difference (6B, bottom panel). When we measured the pole-to-pole distance in control cells, the mean value was 8.4 &#x000b1; 0.4 &#x003bc;m. The mean values derived from GSK-3 inhibitor-treated cells were marginally higher, reaching 10.4 &#x000b1; 0.6 &#x003bc;m in the presence of AR-A014418 (Fig. <xref ref-type="fig" rid="F6">6C</xref>). However that these differences are not statistically significant (Table <xref ref-type="table" rid="T4">4</xref>), possibly reflecting a small effect or our small sample size.</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Effect of GSK-3 inhibitors on spindle morphology</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Parameter</bold></td><td align="center"><bold>Control</bold></td><td align="center"><bold>SB-415286</bold></td><td align="center"><bold>AR-A014418</bold></td><td align="center"><bold>1-Aza kenpaullone</bold></td><td align="center"><bold>CHIR99021</bold></td></tr></thead><tbody><tr><td align="center">Pole-Pole Distance (&#x003bc;m)</td><td align="center">8.39 &#x000b1; 0.45</td><td align="center">9.45 &#x000b1; 0.37</td><td align="center">10.36 &#x000b1; 0.57</td><td align="center">9.06 &#x000b1; 0.39</td><td align="center">8.18 &#x000b1; 0.33</td></tr><tr><td></td><td align="center">(22)*</td><td align="center">(20)</td><td align="center">(19)</td><td align="center">(20)</td><td align="center">(18)</td></tr><tr><td></td><td align="center">-</td><td align="center">p &#x0003e; 0.05<sup>&#x000a7;</sup></td><td align="center">p &#x0003c; 0.05</td><td align="center">p &#x0003e; 0.05</td><td align="center">p &#x0003e; 0.05</td></tr><tr><td align="center">Tubulin Intensity (midzone/cell max)</td><td align="center">0.39 &#x000b1; 0.02</td><td align="center">0.21 &#x000b1; 0.01</td><td align="center">0.25 &#x000b1; 0.01</td><td align="center">0.24 &#x000b1; 0.01</td><td align="center">0.26 &#x000b1; 0.02</td></tr><tr><td></td><td align="center">(15)*</td><td align="center">(20)</td><td align="center">(19)</td><td align="center">(20)</td><td align="center">(18)</td></tr><tr><td></td><td align="center">-</td><td align="center">p &#x0003c; 0.001</td><td align="center">p &#x0003c; 0.01</td><td align="center">p &#x0003c; 0.001</td><td align="center">p &#x0003c; 0.05</td></tr><tr><td align="center">Interkinetochore Distance (&#x003bc;m)</td><td align="center">0.91 &#x000b1; 0.04</td><td align="center">1.04 &#x000b1; 0.03</td><td align="center">1.05 &#x000b1; 0.04</td><td align="center">0.93 &#x000b1; 0.02</td><td align="center">0.92 &#x000b1; 0.02</td></tr><tr><td></td><td align="center">(40, 4)</td><td align="center">(33, 4)</td><td align="center">(20, 3)</td><td align="center">(52, 4)</td><td align="center">(41, 4)</td></tr><tr><td></td><td align="center">-</td><td align="center">p &#x0003c; 0.05</td><td align="center">p &#x0003e; 0.05</td><td align="center">p &#x0003e; 0.05</td><td align="center">p &#x0003e; 0.05</td></tr><tr><td align="center">Bub1 Intensity (Bub1:ACA)</td><td align="center">100.00 &#x000b1; 3.30</td><td align="center">42.59 &#x000b1; 0.85</td><td align="center">24.24 &#x000b1; 0.40</td><td align="center">46.20 &#x000b1; 0.98</td><td align="center">68.50 &#x000b1; 0.79</td></tr><tr><td></td><td align="center">(76, 4)<sup>&#x02021;</sup></td><td align="center">(64, 4)</td><td align="center">(116, 3)</td><td align="center">(81, 4)</td><td align="center">(124, 5)</td></tr><tr><td></td><td align="center">-</td><td align="center">p &#x0003c; 0.05</td><td align="center">p &#x0003c; 0.001</td><td align="center">p &#x0003c; 0.001</td><td align="center">p &#x0003e; 0.05</td></tr><tr><td align="center">BubR1 Intensity (BubR1:ACA)</td><td align="center">100.00 &#x000b1; 0.40</td><td align="center">63.67 &#x000b1; 0.30</td><td align="center">31.49 &#x000b1; 1.24</td><td align="center">89.27 &#x000b1; 0.75</td><td align="center">84.08 &#x000b1; 0.49</td></tr><tr><td></td><td align="center">(121, 7)<sup>&#x02021;</sup></td><td align="center">(115, 6)</td><td align="center">(133, 4)</td><td align="center">(176, 6)</td><td align="center">(127, 5)</td></tr><tr><td></td><td align="center">-</td><td align="center">p &#x0003c; 0.001</td><td align="center">p &#x0003c; 0.001</td><td align="center">p &#x0003c; 0.001</td><td align="center">p &#x0003c; 0.001</td></tr></tbody></table><table-wrap-foot><p>Quantitation of spindle length (pole to pole distance), inter-kinetochore distance and kinetochore localisation of Bub1 and BubR1 in DLD-1 cells treated with GSK-3 inhibitors.</p><p>* Values in parentheses (Number of cells)</p><p><sup>&#x02021; </sup>Values in parentheses (Number of kinetochores, Number of cells)</p><p><sup>&#x000a7; </sup>Kruskal-Wallis Test (Nonparametric ANOVA), Dunn's Multiple Comparisons Test.</p></table-wrap-foot></table-wrap><p>Tubulin intensity along the spindle length was, however, significantly different in drug-treated cells. In the examples shown in Figure <xref ref-type="fig" rid="F6">6B</xref>, the trough between the two peaks &#x02013; which corresponds to the spindle midzone &#x02013; is lower in both cases. Indeed, in control cells, the ratio of tubulin intensity at the midzone compared to the maximum value in that cells was 0.39 &#x000b1; 0.02 (Fig. <xref ref-type="fig" rid="F6">6D</xref>, Table <xref ref-type="table" rid="T4">4</xref>). By contrast, in drug-treated cells this value was reduced to between 0.21 &#x000b1; 0.01 in the presence of SB-415286, and 0.26 &#x000b1; 0.02 in the presence of CHIR99021. Thus, GSK-3 inhibitors do appear to affect spindle morphology.</p></sec><sec><title>GSK-3 inhibitors reduce Bub1 levels at aligned chromosomes</title><p>The spindle checkpoint maintains chromosome stability by delaying anaphase until all the chromosomes are correctly bioriented [<xref ref-type="bibr" rid="B49">49</xref>-<xref ref-type="bibr" rid="B51">51</xref>]. That cells treated with GSK-3 inhibitors delay mitosis in the presence of unaligned chromosomes indicates that the spindle checkpoint is largely intact (Fig. <xref ref-type="fig" rid="F3">3</xref>). Consistently, when exposed to the spindle toxins taxol and nocodazole, SB-415286 treated cells arrest in mitosis (data not shown). However, the spindle checkpoint is capable of delaying anaphase in response to a single unaligned chromosome [<xref ref-type="bibr" rid="B51">51</xref>,<xref ref-type="bibr" rid="B52">52</xref>]. Because drug-treated cells often enter anaphase with unaligned chromosomes (Fig. <xref ref-type="fig" rid="F3">3</xref>), it is possible that the GSK-3 inhibitors suppress the checkpoint signal below the threshold required to detect a single unaligned chromosome. While many factors determine spindle checkpoint signalling [<xref ref-type="bibr" rid="B53">53</xref>,<xref ref-type="bibr" rid="B54">54</xref>], kinetochore localisation of Bub1 and BubR1 is required for full checkpoint function [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B55">55</xref>]. Therefore, we analysed the levels of kinetochore bound Bub1 and BubR1 following drug exposure.</p><p>In control and drug-treated cells, Bub1 and BubR1 were recruited to kinetochores in prophase and prometaphase (not shown). In control cells, Bub1 and BubR1 persisted at metaphase kinetochores, albeit at reduced levels (Fig. <xref ref-type="fig" rid="F7">7A, B</xref>). In drug-treated cells, Bub1 and BubR1 were clearly present at the kinetochores of unaligned chromosomes. Consistent with our previous observations suggesting that Bub1 localisation is attachment-sensitive [<xref ref-type="bibr" rid="B36">36</xref>], Bub1 asymmetrically labelled the kinetochores of mono-oriented chromosomes, with the unattached kinetochore staining stronger (Fig. <xref ref-type="fig" rid="F7">7A, C</xref>). In addition, consistent with our previous notion that BubR1 localisation is tension-sensitive [<xref ref-type="bibr" rid="B36">36</xref>], BubR1 staining was more symmetrical at the kinetochores of mono-oriented chromosomes (Fig. <xref ref-type="fig" rid="F7">7B, C</xref>). Furthermore, pixel intensity-measurements revealed that the levels of Bub1 and BubR1 at these unaligned chromosomes were no different from unaligned kinetochores in control cells (data not shown). Thus, prior to chromosome alignment, the behaviour of Bub1 and BubR1 appear largely normal in the presence of the GSK-3 inhibitors.</p><fig position="float" id="F7"><label>Figure 7</label><caption><p><bold>GSK-3 inhibitors increase inter-kinetochore distance</bold>. Drug-treated DLD-1 cells were fixed and stained to detect centromeres (ACA, red), kinetochores (Bub1 or BubR1, green), microtubules (green or blue) and the chromosomes (red) as indicated. (<bold>A, B</bold>) Projections of deconvolved image stacks showing reduced levels of Bub1 and BubR1 is at metaphase-kinetochores is reduced in GSK-3 inhibitor treated cells. Scale bars: 5 &#x003bc;m. (<bold>C</bold>) Projections of deconvolved image stacks showing the asymmetric labelling of Bub1 on the kinetochore of mono-orientated chromosomes. (<bold>D</bold>) Bar graph quantifying inter-kinetochore distance at metaphase chromosomes. Values represent the mean and s.e.m. derived from at least 20 kinetochores in at least 3 cells. (<bold>E, F</bold>) Bar graphs quantifying the levels of Bub1 and BubR1 at aligned chromosomes. Values represent the mean and s.e.m. derived from at least 64 kinetochores in at least 3 cells. The cells shown in (A) were treated with 30 &#x003bc;M SB-415286 and in (B) with 10 &#x003bc;M CHIR99021.</p></caption><graphic xlink:href="1471-2121-8-34-7"/></fig><p>The abundance of Bub1 and BubR1 at aligned chromosomes was however significantly reduced (Fig. <xref ref-type="fig" rid="F7">7A, B</xref> and Table <xref ref-type="table" rid="T4">4</xref>). Pixel intensity-measurements showed that SB-415286, AR-A014418, 1-Azakenpaullone and CHIR99021 all reduced kinetochore bound Bub1, down to 25% in the case of AR-A014418 (Fig. <xref ref-type="fig" rid="F7">7E</xref> and Table <xref ref-type="table" rid="T4">4</xref>). Kinetochore bound BubR1 was also reduced by all four drugs, most notably by SB-415286 and AR-A014418 (Fig. <xref ref-type="fig" rid="F7">7F</xref> and Table <xref ref-type="table" rid="T4">4</xref>). One explanation for these observations is that the bioriented kinetochores had higher microtubule occupancy and/or were under more tension. To test this, we measured the inter-kinetochore distances of aligned chromosomes. In control cells, the mean inter-kinetochore distance was 0.91 &#x000b1; 0.04 &#x003bc;m. In SB-415286- and AR-A014418-treated cells, this value increased to ~1.05 &#x003bc;m, a statistically significant difference (Fig <xref ref-type="fig" rid="F7">7D</xref> and Table <xref ref-type="table" rid="T4">4</xref>). Although 1-Azakenpaullone and CHIR99021 had little effect, note that there is a correlation between inter-kinetochore distance and BubR1 levels. While SB-415286 and AR-A014418 increased inter-kinetochore distance and reduced BubR1, 1-Azakenpaullone and CHIR99021 had only modest effects on BubR1 binding and inter-kinetochore distance (Table <xref ref-type="table" rid="T4">4</xref>). Significantly, SB-415286 and AR-A014418 also had more penetrant effects on chromosome alignment (Figs <xref ref-type="fig" rid="F2">2C</xref>, <xref ref-type="fig" rid="F3">3D</xref>) and pole-to-pole distance (Fig. <xref ref-type="fig" rid="F6">6C</xref> and Table <xref ref-type="table" rid="T4">4</xref>).</p></sec><sec><title>GSK-3&#x003b2; RNAi induces mitotic defects</title><p>Our observations demonstrate that several different GSK-3 inhibitors effect spindle morphology and chromosome alignment, and elevate the chromosomes missegregation rate. Because we used a panel of structurally diverse compounds (Fig. <xref ref-type="fig" rid="F1">1</xref>), the simplest explanation is that the effects are due to inhibition of GSK-3. However, to rule out the possibility that the phenotypes observed may be due to off-target effects, we asked whether repression of GSK-3&#x003b2; by RNA interference yielded similar effects. We focussed on GSK-3&#x003b2; because this isoform localises to the mitotic spindle [<xref ref-type="bibr" rid="B33">33</xref>]. DLD-1 cells were transfected with siRNA duplexes designed to repress GSK-3&#x003b2; then immunoblotted with an antibody which recognises both GSK-3&#x003b1; and GSK-3&#x003b2;. Importantly, we observed a significant and selective reduction in GSK-3&#x003b2; levels (Fig. <xref ref-type="fig" rid="F8">8A</xref>). In the GSK-3&#x003b2; RNAi population, we frequently observed cells with micronuclei in the GSK-3&#x003b2; RNAi population (Fig. <xref ref-type="fig" rid="F8">8B</xref>), an indicator of chromosome missegregation [<xref ref-type="bibr" rid="B56">56</xref>]. Quantitation revealed that GSK-3&#x003b2; RNAi increased the number of cells with micronuclei by a factor of two 48-hours post transfection, and by almost 4-fold at 72 hours (Fig. <xref ref-type="fig" rid="F8">8C</xref>). Furthermore, we frequently observed metaphase spindles with multiple unaligned chromosomes (Fig. <xref ref-type="fig" rid="F8">8D</xref>). Quantitation showed a greater than 3-fold increase in such figures 72 hours after transfection (Fig. <xref ref-type="fig" rid="F8">8E</xref>). The spindle also appeared abnormal following GSK-3&#x003b2; RNAi, with an increase in astral microtubules (not shown) and an increase in spindle length; the mean pole-to-pole distance following repression of GSK-3&#x003b2; was 8.3 &#x000b1; 0.4 &#x003bc;m compared to 7.7 &#x000b1; 0.3 &#x003bc;m in control cells. Tubulin intensity at the spindle midzone was also significantly reduced (p &#x0003c; 0.05) following GSK-3&#x003b2; RNAi (Fig. <xref ref-type="fig" rid="F8">8F</xref>). BubR1 levels at metaphase kinetochores was significantly reduced; the mean BubR1/ACA ratio was 4.37 &#x000b1; 0.94 in controls compared to 2.76 &#x000b1; 0.24 in GSK-3&#x003b2;-deficient cells (p &#x0003c; 0.05). Inter-kinetochore distance was also significantly increased from 1.02 &#x000b1; 0.03 &#x003bc;m in controls to 1.15 &#x000b1; 0.04 &#x003bc;m following repression of GSK-3&#x003b2; (p &#x0003c; 0.05). Thus, as observed with the small molecule GSK-3 inhibitors, RNAi-mediated repression of GSK-3&#x003b2; affects spindle morphology, inhibits chromosome alignment and the fidelity of chromosome segregation.</p><fig position="float" id="F8"><label>Figure 8</label><caption><p><bold>GSK-3&#x003b2; RNAi inhibits chromosome alignment</bold>. DLD-1 cells were transfected with siRNA duplexes designed to repress GSK-3&#x003b2; then analysed by immunoblot and immunofluorescence. (<bold>A</bold>) Immunoblot showing repression of GSK-3&#x003b2;. (<bold>B</bold>) Images of interphase cells showing micronuclei following repression of GSK3-&#x003b2;. (<bold>C</bold>) Scatter plot quantitating cells with micronuclei. The data is derived from four independent experiments, with each symbol representing an individual coverslip from which a minimum of 1,000 cells was counted. (<bold>D</bold>) Images of mitotic cells showing chromosome alignment defects in GSK-3&#x003b2; deficient cells. Bar = 5 &#x003bc;m. (<bold>E</bold>) Box plot quantitating abnormal metaphases in control (black bar) and GSK-3&#x003b2; RNAi (white bar) populations, 48 and 72 hours after transfection. The data is derived from three independent experiments. (F) Bar graphs quantifying the tubulin intensity at the spindle midzone. Values represent the mean and s.e.m. derived from at least 5 cells.</p></caption><graphic xlink:href="1471-2121-8-34-8"/></fig></sec></sec><sec><title>Discussion</title><sec><title>Small molecule GSK-3 inhibitors inhibit chromosome alignment</title><p>Here, we use small molecule inhibitors to probe GSK-3 function in cell cycle progression and mitotic chromosome segregation. Several inhibitors, including SB-415286, AR-A014418, 1-Azakenpaullone and CHIR99021, all significantly reduced phosphorylation of glycogen synthase in cells, indicating efficient cellular inhibition of GSK-3. Importantly, these four compounds inhibit chromosome alignment. Several other compounds, which reportedly inhibit GSK-3 <italic>in vitro</italic>, had little effect on glycogen synthase phosphorylation and had no effect on chromosome alignment. Why these latter inhibitors did not inhibit GSK-3 activity in cells is unclear but could be due to trivial reasons such as limited permeability. While the mode of action of these latter inhibitors is non-ATP competitive, the inhibitors which did inhibit GSK-3 activity in cells were all ATP competitors. This raises the possibility that their cellular effects may be due to inhibition of other protein kinases. However, all four inhibitors are relatively specific for GSK-3 inhibitors, at least <italic>in vitro </italic>[<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B47">47</xref>,<xref ref-type="bibr" rid="B57">57</xref>,<xref ref-type="bibr" rid="B58">58</xref>]. Furthermore, they are all from different chemical classes and therefore likely to have different spectrums of "off-target" effects. Thus, the simplest explanation is that the chromosome alignment defect is due to inhibition of GSK-3. Indeed, the similarities between the GSK-3&#x003b2; RNAi phenotype and the inhibitor-induced phenotypes lends further weight to this notion. However, it will be important to test this hypothesis further in future studies, in particular the identification and characterisation of drug-resistant GSK3-&#x003b2; mutants will provide a powerful approach to dissecting the role of GSK-3 in cell cycle processes. In addition, analysing the effects these inhibitors have on GSK-3 null cells will help delineate off-target effects.</p></sec><sec><title>Regulation of GSK-3 at the spindle pole</title><p>The observation that phospho-GSK-3&#x003b1;/&#x003b2; (Ser21/9) localises to spindle poles in mitosis [<xref ref-type="bibr" rid="B33">33</xref>], raises the possibility that GSK-3 is somehow involved in regulating microtubule dynamics and/or spindle pole function. Indeed, Wakefield <italic>et al </italic>showed that cells treated with two GSK-3 inhibitors, SB-2 and SB-4 affected spindle assembly and inhibited chromosome alignment. Here, we have extended the observations of Wakefield <italic>et al </italic>by (<italic>a</italic>) using a panel of diverse GSK-3 inhibitors, (<italic>b</italic>) demonstrating that mitotic phenotypes correlate with GSK-3 inhibition and (<italic>c</italic>) further characterising the mitotic defects. In addition, we show that cells treated with GSK-3 inhibitors enter anaphase with unaligned chromosomes. Consistent with Wakefield <italic>et al</italic>, our observations indicate that spindle morphology was frequently abnormal in cells treated with GSK inhibitors, with elevated numbers of astral microtubules. Interestingly, <italic>in vitro</italic>, GSK-3 phosphorylates another centrosomal kinase, Aurora A, on serines 290/291[<xref ref-type="bibr" rid="B59">59</xref>]. This in turn results in Aurora A auto-phosphorylation on serine 349. When S290/291 and S349 were mutated to phospho-mimicing aspartates, Aurora A was less active towards CPEB, a substrate that becomes phosphorylated in <italic>Xenopus </italic>oocytes following progesterone stimulation [<xref ref-type="bibr" rid="B59">59</xref>]. This phosphorylation event results in the translation of mos and Cyclin B mRNAs, which in turn drives cell cycle progression. Conversely, an Aurora A harbouring non-phosphorylatable alanines at 290/291 and 349 was constitutively active towards CPEB. Thus, GSK-3 appears to negatively regulate Aurora A, at least in <italic>Xenpous </italic>oocyte maturation. Whether GSK-3 phosphorylates Aurora A in somatic cells remains to be seen, but evidence from several systems indicate that Aurora A is required for spindle assembly [<xref ref-type="bibr" rid="B60">60</xref>-<xref ref-type="bibr" rid="B62">62</xref>], and recently, we have shown that Aurora A kinase activity is required for spindle assembly in human cells [<xref ref-type="bibr" rid="B63">63</xref>]. Because GSK-3 is inactive when phosphorylated on serine 21/9, it is possible that downregulation of GSK-3 at the spindle poles allows localised Aurora A activation, which in turn modulates microtubule function thereby facilitating spindle assembly. Whether GSK-3 is active away from the centrosome in mitosis remains to be seen, but it is conceivable that drug-mediated inhibition of GSK-3 could result in activation of Aurora A elsewhere in the cell, not just at the spindle pole. This in turn may stabilise microtubules resulting in the excessive asters observed in drug-treated cells.</p></sec><sec><title>GSK-3, kinetochore &#x02013; microtubule interactions and the spindle checkpoint</title><p>Cells treated with GSK-3 inhibitors align most of their chromosomes but have difficulty aligning them all and frequently enter anaphase with unaligned chromosomes. While the spindle defects may be sufficient to explain the chromosome misalignment, it is also possible that GSK-3 inhibition affects kinetochore behaviour. Support for this notion comes from the observation that the spindle checkpoint &#x02013; which requires kinetochore function &#x02013; is attenuated following GSK-3 inhibition. Clearly the spindle checkpoint is largely intact following GSK-3 inhibition: drug-treated cells delay anaphase onset in the presence of unaligned chromosomes (Fig. <xref ref-type="fig" rid="F4">4</xref>) and arrest when the spindle is destroyed with nocodazole (data not shown) However, drug-treated cells do enter anaphase with unaligned chromosomes, something which control cells never do. Furthermore, when HeLa cells were released from a G1/S block into SB-415286 plus nocodazole, the population mounted an attenuated checkpoint response, exhibiting a maximal mitotic index of ~40% (data not shown) compared to ~80% in controls (Fig. <xref ref-type="fig" rid="F3">3</xref>). Why the spindle checkpoint in GSK-3-inhibitor treated cells is attenuated remains to be seen: we did not observe any significant changes with respect to the levels of Bub1 and BubR1 at unaligned kinetochores (not shown). Interestingly however, levels of Bub1 and BubR1 were decreased at kinetochores of aligned chromosomes (Fig. <xref ref-type="fig" rid="F6">6</xref>). Because levels of kinetochore-bound Bub1 and BubR1 are indicators of microtubule occupancy and tension respectively [<xref ref-type="bibr" rid="B36">36</xref>], this suggests that GSK-3-inhibition actually promotes kinetochore &#x02013; microtubule interactions. Consistently, inter-kinetochore distances increase in the presence of SB-415286 and AR-A014414. One possibility is that GSK-3-inhibition affects the spindle checkpoint via APC. Bub1 and BubR1 phosphorylate APC <italic>in vitro</italic>, an event which is enhanced if APC is already phosphorylated by GSK-3 [<xref ref-type="bibr" rid="B15">15</xref>]. Thus, following GSK-3 inhibition, phosphorylation of APC by Bub1 and BubR1 maybe attenuated.</p><p>Recently cells depleted of APC or expressing dominant negative mutants have been shown to have weakened collapsed spindles, defective kinetochore attachments, an increase in levels of kinetochore bound Bub1 and BubR1 and a decrease in tension across the kinetochore [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B64">64</xref>]. However, there appears to be no anaphase delay even though these cells go on and missegregate their chromosomes [<xref ref-type="bibr" rid="B65">65</xref>]. In contrast when GSK-3 is inhibited we observe an increase in spindle length and astral microtubules, a decrease in the level of kinetochore bound Bub1 and BubR1, an increase in the interkinetochore distance and a delay in chromosome alignment. This raises the possibility that GSK-3 negatively regulates APC's mitotic functions such that inhibiting GSK-3 activates APC, thereby yielding the opposite phenotype to APC depletion. Indeed inhibition of GSK-3 increases APC-microtubule interactions [<xref ref-type="bibr" rid="B13">13</xref>] which may help stabilise kinetochore-microtubule interactions.</p></sec></sec><sec><title>Conclusion</title><sec><title>GSK-3 and CIN</title><p>Our observations show that, at least in cultured cells, GSK-3 inhibitors induce chromosome non-disjunction, a phenotype that we also observed following RNAi-mediated repression of GSK-3&#x003b2;. Although GSK-3 inhibition affects spindle morphology, the chromosome alignment defect is the major contributing factor to non-disjunction. Is it possible that GSK-3 dysfunction causes chromosome instability in tumours? We feel that this is unlikely. Firstly, GSK-3 is rarely mutated in cancer [<xref ref-type="bibr" rid="B66">66</xref>]. Secondly, mouse knockouts are embryonic lethal [<xref ref-type="bibr" rid="B67">67</xref>]. Thus, in light of its essential and multi-faceted functions, GSK-3 dysfunction is likely to lead to cell death rather than provide a growth advantage. However, GSK-3 inhibitors are currently being investigated as potential therapeutics for a variety of chronic diseases such as diabetes and neurodegenerative disorders. Our observations suggest that GSK-3 inhibitors may have an unexpected consequence in these settings, namely the induction of chromosome instability, which may in turn promote tumourigenesis. Efforts to determine whether GSK-3 inhibitors induce chromosome instability in mouse models and patients seem to us to be imperative.</p></sec></sec><sec sec-type="methods"><title>Methods</title><sec><title>Cell culture and GSK-3 inhibitors</title><p>HeLa, HCT116, DLD-1 and DLD-1 cells stably expressing GFP-Histone H2B were all as described previously [<xref ref-type="bibr" rid="B38">38</xref>]. Cell culture conditions were as described [<xref ref-type="bibr" rid="B36">36</xref>]. Nocodazole (Sigma, 10 mg/ml in DMSO) was used at a final concentration of 0.2 &#x003bc;g/ml. The proteasome inhibitor MG132 (Calbiochem, 20 mM in DMSO) was used at a final concentration of 20 &#x003bc;M. RO-31-8220 (Calbiochem, 10 mM in DMSO) was used at a final concentration of 10 &#x003bc;M. SB-415286 (Tocris; 25 mM), TDZD-8 (Calbiochem; 20 mM), Inhibitor II (Calbiochem, 25 mM), OTDZT (Calbiochem; 31.8 mM), Inhibitor XI (Calbiochem; 25 mM), 1-Azakenpaullone (Calbiochem; 25 mM), AR-A014418 (Calbiochem, 25 mM), and CHIR99021 (kind gift from Philip Cohen; 10 mM) were dissolved in DMSO at the concentrations indicated, stored at -20&#x000b0;C in individual aliquots to avoid freeze thaw cycles, then freshly diluted in media. DMSO was added to control cultures to account for the solvent. Lithium Chloride (BDH) was dissolved in water at concentration of 1 M, filter sterilised and used at a final concentration of 40 mM.</p></sec><sec><title>Antibody Techniques</title><p>Immunoblotting was done as described previously [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B36">36</xref>] using the following antibodies: rabbit anti-phospho-glycogen synthase (Cell Signalling Tech, 1:1,000); mouse anti-glycogen synthase kinase 3 (4G-1E, Upstate, 1:500); mouse anti-phospho-nucleolin (TG3, kindly provided by Peter Davies, 1:25); sheep anti-Bub3 (SB3.2, 1:1000). Immunofluorescence was done as described [<xref ref-type="bibr" rid="B21">21</xref>] using the following antibodies: TAT-1, mouse anti-tubulin (1:100, ref. [<xref ref-type="bibr" rid="B68">68</xref>]); SBR1.1, sheep anti-BubR1 (1:1,000, ref [<xref ref-type="bibr" rid="B36">36</xref>]); SB1.3, sheep anti-Bub1 (1:1,000, ref [<xref ref-type="bibr" rid="B36">36</xref>]); ACA, human anti-centromere (kindly provided by Bill Earnshaw, 1:800). To analyse kinetochore &#x02013; microtubule interactions and spindle morphology, cells were permeabilised for 90 seconds in a microtubule stabilising buffer (100 mM PIPES pH 6.8, 1 Mm MgCl, 0.1 Mm CaCl<sub>2</sub>, 0.1% Triton X-100), fixed for 10 minutes in 4% formaldehyde, then blocked and incubated with the appropriate primary antibodies as described above. Following washes with PBST, cells were stained for 30 minutes at room temperature with the appropriate Cy2-, Cy3- or Cy5- conjugated secondary antibodies (Jackson Immuno-Research Laboratories), all diluted 1:500. Following washes, cells were stained with Hoechst 33358 at 1 &#x003bc;g/ml in PBST then mounted in 90% glycerol, 20 mM Tris-HCl pH 8.0. Deconvolution microscopy and pixel intensity quantitation was performed using a wide field optical sectioning microscope (Deltavision, Applied Precision) as described previously [<xref ref-type="bibr" rid="B36">36</xref>]. Briefly, for each cell, a Z-series of images at 0.2 &#x003bc;m intervals was captured at each wavelength and then processed using constrained iterative deconvolution. Deconvolved image stacks were projected and fluorescence signal intensities quantified using SoftWoRx (Applied Precision). To quantify the kinetochore bound protein, the average pixel intensities from at least 64 kinetochores from three or more cells was measured, background readings were subtracted and the values were then normalised against the ACA signal to account for any variations in staining or image acquisition. SoftWoRx was used to measure inter-kinetochore distance using Bub1 foci as indicated to determine kinetochore position. Tubulin intensity was determined as described previously [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B48">48</xref>]. Statistical analysis was performed using InStat<sup>&#x000ae;</sup>v3.0 (GraphPad Software Inc).</p></sec><sec><title>Cell biology</title><p>DNA content and mitotic index measurements and synchronisation of TA-HeLa cells at G1/S using double thymidine block were done as described previously [<xref ref-type="bibr" rid="B37">37</xref>], but using an FSE-conjugated MPM-2 antibody (Upstate Biotech). At least 10,000 cells were then analysed on a FACSCAN (Becton Dickson). For time-lapse analysis, DLD-1 cells expressing the GFP-Histone fusion protein were cultured on either individual 35 mm glass bottomed Petri dishes or 35 mm glass bottomed 6-well plates (MatTek Co). Microscopy was performed on a manual Axiovert 200 (Zeiss), equipped with a PZ-2000 automated stage (Applied Scientific Instrumentation) and an environmental control chamber (Solent Scientific), which maintained the cells at 37&#x000b0;C in a humidified stream of 5% CO<sub>2</sub>, 95% air. Shutters, filter wheels and point visiting were driven by Metamorph software (Universal Imaging). Images were taken using a CoolSNAP HQ camera (Photometrics), while individual TIFF files were imported into Photoshop (Adobe) for printing or QuickTime (Apple) for movies. Nuclear envelope breakdown (NEB) was judged as the point when the prophase chromatin lost a smooth, linear periphery and the time of anaphase onset to be the first frame where coordinated pole wards movement was observed. Mitotic timing data is presented as box-and-whisker plots generated with Prism 4 (GraphPad), where the boxes show the median and interquartile range, while the whiskers show the entire range.</p></sec><sec><title>RNAi</title><p>siRNA duplexes (SMARTpool, Dharmacon Research) designed to repress GSK-3&#x003b2; or non-specific control pool duplexes or siRNA duplexes designed to target lamin B1were transfected into DLD-1 cells using OligofectAMINE&#x02122; (Invitrogen) as describe [<xref ref-type="bibr" rid="B69">69</xref>]. In brief, 4 &#x000d7; 10<sup>4 </sup>cells were seeded in 24-well plates 24 hours prior to transfection in growth media without antibiotics. siRNA duplexes were mixed with OligofectAMINE&#x02122; in OptiMEM media without antibiotics and incubated for 20 minutes. siRNA/lipid complexes were then added to cells for 6 hours followed by addition of complete media containing 20% foetal calf serum. 24 hours later the cells were replated onto coverslips or 6 well plates then analysed 24 hours later.</p></sec></sec><sec><title>Authors' contributions</title><p>Project conceived and experiments designed by AT and SST. Experiments carried out by AT assisted by AR and OS. Manuscript prepared by AT and SST.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>For generously providing reagents, we are indebted to Philip Cohen (Dundee), Peter Davies (New York) and Bill Earnshaw (Edinburgh). AT was funded by the Association for International Cancer Research. AR and OS were funded by studentships from the Wellcome Trust and the M.R.C. respectively. SST is a Cancer Research UK Senior Fellow.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicklas</surname><given-names>RB</given-names></name></person-group><article-title>How cells get the right chromosomes</article-title><source>Science</source><year>1997</year><volume>275</volume><fpage>632</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">9005842</pub-id><pub-id pub-id-type="doi">10.1126/science.275.5300.632</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>GK</given-names></name><name><surname>Liu</surname><given-names>ST</given-names></name><name><surname>Yen</surname><given-names>TJ</given-names></name></person-group><article-title>Kinetochore structure and function</article-title><source>Trends Cell Biol</source><year>2005</year><volume>15</volume><fpage>589</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">16214339</pub-id><pub-id pub-id-type="doi">10.1016/j.tcb.2005.09.010</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cleveland</surname><given-names>DW</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Sullivan</surname><given-names>KF</given-names></name></person-group><article-title>Centromeres and kinetochores: from epigenetics to mitotic checkpoint signaling</article-title><source>Cell</source><year>2003</year><volume>112</volume><fpage>407</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">12600307</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(03)00115-6</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maiato</surname><given-names>H</given-names></name><name><surname>DeLuca</surname><given-names>J</given-names></name><name><surname>Salmon</surname><given-names>ED</given-names></name><name><surname>Earnshaw</surname><given-names>WC</given-names></name></person-group><article-title>The dynamic kinetochore-microtubule interface</article-title><source>J Cell Sci</source><year>2004</year><volume>117</volume><fpage>5461</fpage><lpage>5477</lpage><pub-id pub-id-type="pmid">15509863</pub-id><pub-id pub-id-type="doi">10.1242/jcs.01536</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>PD</given-names></name><name><surname>Knatko</surname><given-names>E</given-names></name><name><surname>Moore</surname><given-names>WJ</given-names></name><name><surname>Swedlow</surname><given-names>JR</given-names></name></person-group><article-title>Mitotic mechanics: the auroras come into view</article-title><source>Curr Opin Cell Biol</source><year>2003</year><volume>15</volume><fpage>672</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">14644191</pub-id><pub-id pub-id-type="doi">10.1016/j.ceb.2003.10.013</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinsky</surname><given-names>BA</given-names></name><name><surname>Biggins</surname><given-names>S</given-names></name></person-group><article-title>The spindle checkpoint: tension versus attachment</article-title><source>Trends Cell Biol</source><year>2005</year><volume>15</volume><fpage>486</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">16084093</pub-id><pub-id pub-id-type="doi">10.1016/j.tcb.2005.07.005</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kops</surname><given-names>GJ</given-names></name><name><surname>Weaver</surname><given-names>BA</given-names></name><name><surname>Cleveland</surname><given-names>DW</given-names></name></person-group><article-title>On the road to cancer: aneuploidy and the mitotic checkpoint</article-title><source>Nat Rev Cancer</source><year>2005</year><volume>5</volume><fpage>773</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">16195750</pub-id><pub-id pub-id-type="doi">10.1038/nrc1714</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>CA</given-names></name><name><surname>Miller</surname><given-names>JR</given-names></name></person-group><article-title>Non-traditional roles for the Adenomatous Polyposis Coli (APC) tumor suppressor protein</article-title><source>Gene</source><year>2005</year><volume>361</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">16185824</pub-id><pub-id pub-id-type="doi">10.1016/j.gene.2005.07.024</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nathke</surname><given-names>IS</given-names></name></person-group><article-title>The adenomatous polyposis coli protein: the Achilles heel of the gut epithelium</article-title><source>Annu Rev Cell Dev Biol</source><year>2004</year><volume>20</volume><fpage>337</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">15473844</pub-id><pub-id pub-id-type="doi">10.1146/annurev.cellbio.20.012103.094541</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bienz</surname><given-names>M</given-names></name></person-group><article-title>The subcellular destinations of APC proteins</article-title><source>Nat Rev Mol Cell Biol</source><year>2002</year><volume>3</volume><fpage>328</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">11988767</pub-id><pub-id pub-id-type="doi">10.1038/nrm806</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Radtke</surname><given-names>F</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Self-renewal and cancer of the gut: two sides of a coin</article-title><source>Science</source><year>2005</year><volume>307</volume><fpage>1904</fpage><lpage>1909</lpage><pub-id pub-id-type="pmid">15790842</pub-id><pub-id pub-id-type="doi">10.1126/science.1104815</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sieber</surname><given-names>OM</given-names></name><name><surname>Tomlinson</surname><given-names>IP</given-names></name><name><surname>Lamlum</surname><given-names>H</given-names></name></person-group><article-title>The adenomatous polyposis coli (APC) tumour suppressor--genetics, function and disease</article-title><source>Mol Med Today</source><year>2000</year><volume>6</volume><fpage>462</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">11099951</pub-id><pub-id pub-id-type="doi">10.1016/S1357-4310(00)01828-1</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zumbrunn</surname><given-names>J</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Hyman</surname><given-names>AA</given-names></name><name><surname>Nathke</surname><given-names>IS</given-names></name></person-group><article-title>Binding of the adenomatous polyposis coli protein to microtubules increases microtubule stability and is regulated by GSK3 beta phosphorylation</article-title><source>Curr Biol</source><year>2001</year><volume>11</volume><fpage>44</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">11166179</pub-id><pub-id pub-id-type="doi">10.1016/S0960-9822(01)00002-1</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fodde</surname><given-names>R</given-names></name><name><surname>Kuipers</surname><given-names>J</given-names></name><name><surname>Rosenberg</surname><given-names>C</given-names></name><name><surname>Smits</surname><given-names>R</given-names></name><name><surname>Kielman</surname><given-names>M</given-names></name><name><surname>Gaspar</surname><given-names>C</given-names></name><name><surname>van Es</surname><given-names>JH</given-names></name><name><surname>Breukel</surname><given-names>C</given-names></name><name><surname>Wiegant</surname><given-names>J</given-names></name><name><surname>Giles</surname><given-names>RH</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Mutations in the APC tumour suppressor gene cause chromosomal instability</article-title><source>Nat Cell Biol</source><year>2001</year><volume>3</volume><fpage>433</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">11283620</pub-id><pub-id pub-id-type="doi">10.1038/35070129</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>KB</given-names></name><name><surname>Burds</surname><given-names>AA</given-names></name><name><surname>Swedlow</surname><given-names>JR</given-names></name><name><surname>Bekir</surname><given-names>SS</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name><name><surname>Nathke</surname><given-names>IS</given-names></name></person-group><article-title>A role for the Adenomatous Polyposis Coli protein in chromosome segregation</article-title><source>Nat Cell Biol</source><year>2001</year><volume>3</volume><fpage>429</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">11283619</pub-id><pub-id pub-id-type="doi">10.1038/35070123</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>RA</given-names></name><name><surname>Kaplan</surname><given-names>KB</given-names></name></person-group><article-title>Chromosome instability in colorectal tumor cells is associated with defects in microtubule plus-end attachments caused by a dominant mutation in APC</article-title><source>J Cell Biol</source><year>2003</year><volume>163</volume><fpage>949</fpage><lpage>961</lpage><pub-id pub-id-type="pmid">14662741</pub-id><pub-id pub-id-type="doi">10.1083/jcb.200307070</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>RA</given-names></name><name><surname>Wollman</surname><given-names>R</given-names></name><name><surname>Kaplan</surname><given-names>KB</given-names></name></person-group><article-title>APC and EB1 function together in mitosis to regulate spindle dynamics and chromosome alignment</article-title><source>Mol Biol Cell</source><year>2005</year><volume>16</volume><fpage>4609</fpage><lpage>4622</lpage><pub-id pub-id-type="pmid">16030254</pub-id><pub-id pub-id-type="doi">10.1091/mbc.E05-03-0259</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dikovskaya</surname><given-names>D</given-names></name><name><surname>Newton</surname><given-names>IP</given-names></name><name><surname>Nathke</surname><given-names>IS</given-names></name></person-group><article-title>The adenomatous polyposis coli protein is required for the formation of robust spindles formed in CSF Xenopus extracts</article-title><source>Mol Biol Cell</source><year>2004</year><volume>15</volume><fpage>2978</fpage><lpage>2991</lpage><pub-id pub-id-type="pmid">15075372</pub-id><pub-id pub-id-type="doi">10.1091/mbc.E03-08-0613</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Louie</surname><given-names>RK</given-names></name><name><surname>Bahmanyar</surname><given-names>S</given-names></name><name><surname>Siemers</surname><given-names>KA</given-names></name><name><surname>Votin</surname><given-names>V</given-names></name><name><surname>Chang</surname><given-names>P</given-names></name><name><surname>Stearns</surname><given-names>T</given-names></name><name><surname>Nelson</surname><given-names>WJ</given-names></name><name><surname>Barth</surname><given-names>AI</given-names></name></person-group><article-title>Adenomatous polyposis coli and EB1 localize in close proximity of the mother centriole and EB1 is a functional component of centrosomes</article-title><source>J Cell Sci</source><year>2004</year><volume>117</volume><fpage>1117</fpage><lpage>1128</lpage><pub-id pub-id-type="pmid">14970257</pub-id><pub-id pub-id-type="doi">10.1242/jcs.00939</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tighe</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>VL</given-names></name><name><surname>Albertella</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><article-title>Aneuploid colon cancer cells have a robust spindle checkpoint</article-title><source>EMBO Rep</source><year>2001</year><volume>2</volume><fpage>609</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">11454737</pub-id><pub-id pub-id-type="doi">10.1093/embo-reports/kve127</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tighe</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>VL</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><article-title>Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability</article-title><source>J Cell Sci</source><year>2004</year><volume>117</volume><fpage>6339</fpage><lpage>6353</lpage><pub-id pub-id-type="pmid">15561772</pub-id><pub-id pub-id-type="doi">10.1242/jcs.01556</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>YM</given-names></name><name><surname>Jones</surname><given-names>DL</given-names></name><name><surname>Fuller</surname><given-names>MT</given-names></name></person-group><article-title>Orientation of asymmetric stem cell division by the APC tumor suppressor and centrosome</article-title><source>Science</source><year>2003</year><volume>301</volume><fpage>1547</fpage><lpage>1550</lpage><pub-id pub-id-type="pmid">12970569</pub-id><pub-id pub-id-type="doi">10.1126/science.1087795</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>CV</given-names></name><name><surname>Yang</surname><given-names>YM</given-names></name><name><surname>Swamy</surname><given-names>MV</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Mahmood</surname><given-names>R</given-names></name><name><surname>Jhanwar-Uniyal</surname><given-names>M</given-names></name><name><surname>Dai</surname><given-names>W</given-names></name></person-group><article-title>Colonic tumorigenesis in BubR1+/-ApcMin/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>4365</fpage><lpage>4370</lpage><pub-id pub-id-type="pmid">15767571</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0407822102</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tirnauer</surname><given-names>JS</given-names></name><name><surname>Bierer</surname><given-names>BE</given-names></name></person-group><article-title>EB1 proteins regulate microtubule dynamics, cell polarity, and chromosome stability</article-title><source>J Cell Biol</source><year>2000</year><volume>149</volume><fpage>761</fpage><lpage>766</lpage><pub-id pub-id-type="pmid">10811817</pub-id><pub-id pub-id-type="doi">10.1083/jcb.149.4.761</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaughan</surname><given-names>KT</given-names></name></person-group><article-title>TIP maker and TIP marker; EB1 as a master controller of microtubule plus ends</article-title><source>J Cell Biol</source><year>2005</year><volume>171</volume><fpage>197</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">16247021</pub-id><pub-id pub-id-type="doi">10.1083/jcb.200509150</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>LK</given-names></name><name><surname>Burrell</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>DE</given-names></name><name><surname>Gyuris</surname><given-names>J</given-names></name><name><surname>Brent</surname><given-names>R</given-names></name><name><surname>Wiltshire</surname><given-names>R</given-names></name><name><surname>Trent</surname><given-names>J</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><article-title>APC binds to the novel protein EB1</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>2972</fpage><lpage>2977</lpage><pub-id pub-id-type="pmid">7606712</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name></person-group><article-title>GSK3 inhibitors: development and therapeutic potential</article-title><source>Nat Rev Drug Discov</source><year>2004</year><volume>3</volume><fpage>479</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">15173837</pub-id><pub-id pub-id-type="doi">10.1038/nrd1415</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doble</surname><given-names>BW</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name></person-group><article-title>GSK-3: tricks of the trade for a multi-tasking kinase</article-title><source>J Cell Sci</source><year>2003</year><volume>116</volume><fpage>1175</fpage><lpage>1186</lpage><pub-id pub-id-type="pmid">12615961</pub-id><pub-id pub-id-type="doi">10.1242/jcs.00384</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jope</surname><given-names>RS</given-names></name><name><surname>Johnson</surname><given-names>GV</given-names></name></person-group><article-title>The glamour and gloom of glycogen synthase kinase-3</article-title><source>Trends Biochem Sci</source><year>2004</year><volume>29</volume><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">15102436</pub-id><pub-id pub-id-type="doi">10.1016/j.tibs.2003.12.004</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morfini</surname><given-names>G</given-names></name><name><surname>Szebenyi</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>H</given-names></name><name><surname>Pant</surname><given-names>HC</given-names></name><name><surname>Pigino</surname><given-names>G</given-names></name><name><surname>DeBoer</surname><given-names>S</given-names></name><name><surname>Beffert</surname><given-names>U</given-names></name><name><surname>Brady</surname><given-names>ST</given-names></name></person-group><article-title>A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons</article-title><source>Embo J</source><year>2004</year><volume>23</volume><fpage>2235</fpage><lpage>2245</lpage><pub-id pub-id-type="pmid">15152189</pub-id><pub-id pub-id-type="doi">10.1038/sj.emboj.7600237</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Welcker</surname><given-names>M</given-names></name><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Loeb</surname><given-names>KR</given-names></name><name><surname>Grim</surname><given-names>J</given-names></name><name><surname>Bloecher</surname><given-names>A</given-names></name><name><surname>Gurien-West</surname><given-names>M</given-names></name><name><surname>Clurman</surname><given-names>BE</given-names></name><name><surname>Roberts</surname><given-names>JM</given-names></name></person-group><article-title>Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation</article-title><source>Mol Cell</source><year>2003</year><volume>12</volume><fpage>381</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">14536078</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(03)00287-9</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciani</surname><given-names>L</given-names></name><name><surname>Krylova</surname><given-names>O</given-names></name><name><surname>Smalley</surname><given-names>MJ</given-names></name><name><surname>Dale</surname><given-names>TC</given-names></name><name><surname>Salinas</surname><given-names>PC</given-names></name></person-group><article-title>A divergent canonical WNT-signaling pathway regulates microtubule dynamics: dishevelled signals locally to stabilize microtubules</article-title><source>J Cell Biol</source><year>2004</year><volume>164</volume><fpage>243</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">14734535</pub-id><pub-id pub-id-type="doi">10.1083/jcb.200309096</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wakefield</surname><given-names>JG</given-names></name><name><surname>Stephens</surname><given-names>DJ</given-names></name><name><surname>Tavare</surname><given-names>JM</given-names></name></person-group><article-title>A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment</article-title><source>J Cell Sci</source><year>2003</year><volume>116</volume><fpage>637</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">12538764</pub-id><pub-id pub-id-type="doi">10.1242/jcs.00273</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Puziss</surname><given-names>JW</given-names></name><name><surname>Hardy</surname><given-names>TA</given-names></name><name><surname>Johnson</surname><given-names>RB</given-names></name><name><surname>Roach</surname><given-names>PJ</given-names></name><name><surname>Hieter</surname><given-names>P</given-names></name></person-group><article-title>MDS1, a dosage suppressor of an mck1 mutant, encodes a putative yeast homolog of glycogen synthase kinase 3</article-title><source>Mol Cell Biol</source><year>1994</year><volume>14</volume><fpage>831</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">8264650</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goshima</surname><given-names>G</given-names></name><name><surname>Iwasaki</surname><given-names>O</given-names></name><name><surname>Obuse</surname><given-names>C</given-names></name><name><surname>Yanagida</surname><given-names>M</given-names></name></person-group><article-title>The role of Ppe1/PP6 phosphatase for equal chromosome segregation in fission yeast kinetochore</article-title><source>Embo J</source><year>2003</year><volume>22</volume><fpage>2752</fpage><lpage>2763</lpage><pub-id pub-id-type="pmid">12773390</pub-id><pub-id pub-id-type="doi">10.1093/emboj/cdg266</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Hussein</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Elderkin</surname><given-names>S</given-names></name><name><surname>Morrow</surname><given-names>CJ</given-names></name></person-group><article-title>Kinetochore localisation and phosphorylation of the mitotic checkpoint components Bub1 and BubR1 are differentially regulated by spindle events in human cells</article-title><source>J Cell Sci</source><year>2001</year><volume>114</volume><fpage>4385</fpage><lpage>4395</lpage><pub-id pub-id-type="pmid">11792804</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>McKeon</surname><given-names>F</given-names></name></person-group><article-title>Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage</article-title><source>Cell</source><year>1997</year><volume>89</volume><fpage>727</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">9182760</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80255-X</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>CJ</given-names></name><name><surname>Tighe</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>VL</given-names></name><name><surname>Scott</surname><given-names>MI</given-names></name><name><surname>Ditchfield</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><article-title>Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20</article-title><source>J Cell Sci</source><year>2005</year><volume>118</volume><fpage>3639</fpage><lpage>3652</lpage><pub-id pub-id-type="pmid">16046481</pub-id><pub-id pub-id-type="doi">10.1242/jcs.02487</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Frame</surname><given-names>S</given-names></name></person-group><article-title>The renaissance of GSK3</article-title><source>Nat Rev Mol Cell Biol</source><year>2001</year><volume>2</volume><fpage>769</fpage><lpage>776</lpage><pub-id pub-id-type="pmid">11584304</pub-id><pub-id pub-id-type="doi">10.1038/35096075</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>PJ</given-names></name><name><surname>Caudwell</surname><given-names>FB</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name></person-group><article-title>Glycogen synthase from rabbit skeletal muscle; effect of insulin on the state of phosphorylation of the seven phosphoserine residues in vivo</article-title><source>Eur J Biochem</source><year>1983</year><volume>130</volume><fpage>227</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">6402364</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>PS</given-names></name><name><surname>Melton</surname><given-names>DA</given-names></name></person-group><article-title>A molecular mechanism for the effect of lithium on development</article-title><source>Proc Natl Acad Sci U S A</source><year>1996</year><volume>93</volume><fpage>8455</fpage><lpage>8459</lpage><pub-id pub-id-type="pmid">8710892</pub-id><pub-id pub-id-type="doi">10.1073/pnas.93.16.8455</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stambolic</surname><given-names>V</given-names></name><name><surname>Ruel</surname><given-names>L</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name></person-group><article-title>Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells</article-title><source>Curr Biol</source><year>1996</year><volume>6</volume><fpage>1664</fpage><lpage>1668</lpage><pub-id pub-id-type="pmid">8994831</pub-id><pub-id pub-id-type="doi">10.1016/S0960-9822(02)70790-2</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Potapova</surname><given-names>TA</given-names></name><name><surname>Daum</surname><given-names>JR</given-names></name><name><surname>Pittman</surname><given-names>BD</given-names></name><name><surname>Hudson</surname><given-names>JR</given-names></name><name><surname>Jones</surname><given-names>TN</given-names></name><name><surname>Satinover</surname><given-names>DL</given-names></name><name><surname>Stukenberg</surname><given-names>PT</given-names></name><name><surname>Gorbsky</surname><given-names>GJ</given-names></name></person-group><article-title>The reversibility of mitotic exit in vertebrate cells</article-title><source>Nature</source><year>2006</year><volume>440</volume><fpage>954</fpage><lpage>958</lpage><pub-id pub-id-type="pmid">16612388</pub-id><pub-id pub-id-type="doi">10.1038/nature04652</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coghlan</surname><given-names>MP</given-names></name><name><surname>Culbert</surname><given-names>AA</given-names></name><name><surname>Cross</surname><given-names>DA</given-names></name><name><surname>Corcoran</surname><given-names>SL</given-names></name><name><surname>Yates</surname><given-names>JW</given-names></name><name><surname>Pearce</surname><given-names>NJ</given-names></name><name><surname>Rausch</surname><given-names>OL</given-names></name><name><surname>Murphy</surname><given-names>GJ</given-names></name><name><surname>Carter</surname><given-names>PS</given-names></name><name><surname>Roxbee Cox</surname><given-names>L</given-names></name><name><surname>Mills</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>MJ</given-names></name><name><surname>Haigh</surname><given-names>D</given-names></name><name><surname>Ward</surname><given-names>RW</given-names></name><name><surname>Smith</surname><given-names>DG</given-names></name><name><surname>Murray</surname><given-names>KJ</given-names></name><name><surname>Reith</surname><given-names>AD</given-names></name><name><surname>Holder</surname><given-names>JC</given-names></name></person-group><article-title>Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription</article-title><source>Chem Biol</source><year>2000</year><volume>7</volume><fpage>793</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">11033082</pub-id><pub-id pub-id-type="doi">10.1016/S1074-5521(00)00025-9</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lochhead</surname><given-names>PA</given-names></name><name><surname>Coghlan</surname><given-names>M</given-names></name><name><surname>Rice</surname><given-names>SQ</given-names></name><name><surname>Sutherland</surname><given-names>C</given-names></name></person-group><article-title>Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression</article-title><source>Diabetes</source><year>2001</year><volume>50</volume><fpage>937</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">11334436</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.50.5.937</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cline</surname><given-names>GW</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name><name><surname>Regittnig</surname><given-names>W</given-names></name><name><surname>Perret</surname><given-names>P</given-names></name><name><surname>Tozzo</surname><given-names>E</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Damico</surname><given-names>C</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name></person-group><article-title>Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><fpage>2903</fpage><lpage>2910</lpage><pub-id pub-id-type="pmid">12351425</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.51.10.2903</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ring</surname><given-names>DB</given-names></name><name><surname>Johnson</surname><given-names>KW</given-names></name><name><surname>Henriksen</surname><given-names>EJ</given-names></name><name><surname>Nuss</surname><given-names>JM</given-names></name><name><surname>Goff</surname><given-names>D</given-names></name><name><surname>Kinnick</surname><given-names>TR</given-names></name><name><surname>Ma</surname><given-names>ST</given-names></name><name><surname>Reeder</surname><given-names>JW</given-names></name><name><surname>Samuels</surname><given-names>I</given-names></name><name><surname>Slabiak</surname><given-names>T</given-names></name><name><surname>Wagman</surname><given-names>AS</given-names></name><name><surname>Hammond</surname><given-names>ME</given-names></name><name><surname>Harrison</surname><given-names>SD</given-names></name></person-group><article-title>Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>588</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">12606497</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.52.3.588</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>SV</given-names></name><name><surname>Vergnolle</surname><given-names>MA</given-names></name><name><surname>Hussein</surname><given-names>D</given-names></name><name><surname>Wozniak</surname><given-names>MJ</given-names></name><name><surname>Allan</surname><given-names>VJ</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><article-title>Silencing Cenp-F weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint</article-title><source>J Cell Sci</source><year>2005</year><volume>118</volume><fpage>4889</fpage><lpage>4900</lpage><pub-id pub-id-type="pmid">16219694</pub-id><pub-id pub-id-type="doi">10.1242/jcs.02614</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>MS</given-names></name><name><surname>Gorbsky</surname><given-names>GJ</given-names></name></person-group><article-title>Microinjection of mitotic cells with the 3F3/2 anti-phosphoepitope antibody delays the onset of anaphase</article-title><source>J Cell Biol</source><year>1995</year><volume>129</volume><fpage>1195</fpage><lpage>1204</lpage><pub-id pub-id-type="pmid">7775567</pub-id><pub-id pub-id-type="doi">10.1083/jcb.129.5.1195</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Nicklas</surname><given-names>RB</given-names></name></person-group><article-title>Mitotic forces control a cell-cycle checkpoint</article-title><source>Nature</source><year>1995</year><volume>373</volume><fpage>630</fpage><lpage>632</lpage><pub-id pub-id-type="pmid">7854422</pub-id><pub-id pub-id-type="doi">10.1038/373630a0</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rieder</surname><given-names>CL</given-names></name><name><surname>Cole</surname><given-names>RW</given-names></name><name><surname>Khodjakov</surname><given-names>A</given-names></name><name><surname>Sluder</surname><given-names>G</given-names></name></person-group><article-title>The checkpoint delaying anaphase in response to chromosome monoorientation is mediated by an inhibitory signal produced by unattached kinetochores</article-title><source>J Cell Biol</source><year>1995</year><volume>130</volume><fpage>941</fpage><lpage>948</lpage><pub-id pub-id-type="pmid">7642709</pub-id><pub-id pub-id-type="doi">10.1083/jcb.130.4.941</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rieder</surname><given-names>CL</given-names></name><name><surname>Schultz</surname><given-names>A</given-names></name><name><surname>Cole</surname><given-names>R</given-names></name><name><surname>Sluder</surname><given-names>G</given-names></name></person-group><article-title>Anaphase onset in vertebrate somatic cells is controlled by a checkpoint that monitors sister kinetochore attachment to the spindle</article-title><source>J Cell Biol</source><year>1994</year><volume>127</volume><fpage>1301</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">7962091</pub-id><pub-id pub-id-type="doi">10.1083/jcb.127.5.1301</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Musacchio</surname><given-names>A</given-names></name><name><surname>Hardwick</surname><given-names>KG</given-names></name></person-group><article-title>The spindle checkpoint: structural insights into dynamic signalling</article-title><source>Nat Rev Mol Cell Biol</source><year>2002</year><volume>3</volume><fpage>731</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">12360190</pub-id><pub-id pub-id-type="doi">10.1038/nrm929</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Scott</surname><given-names>MI</given-names></name><name><surname>Holland</surname><given-names>AJ</given-names></name></person-group><article-title>The spindle checkpoint: a quality control mechanism which ensures accurate chromosome segregation</article-title><source>Chromosome Res</source><year>2004</year><volume>12</volume><fpage>599</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">15289666</pub-id><pub-id pub-id-type="doi">10.1023/B:CHRO.0000036610.78380.51</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>VL</given-names></name><name><surname>Scott</surname><given-names>MI</given-names></name><name><surname>Holt</surname><given-names>SV</given-names></name><name><surname>Hussein</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><article-title>Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression</article-title><source>J Cell Sci</source><year>2004</year><volume>117</volume><fpage>1577</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">15020684</pub-id><pub-id pub-id-type="doi">10.1242/jcs.01006</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffelder</surname><given-names>DR</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Burke</surname><given-names>NA</given-names></name><name><surname>Watkins</surname><given-names>SC</given-names></name><name><surname>Gollin</surname><given-names>SM</given-names></name><name><surname>Saunders</surname><given-names>WS</given-names></name></person-group><article-title>Resolution of anaphase bridges in cancer cells</article-title><source>Chromosoma</source><year>2004</year><volume>112</volume><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">15156327</pub-id><pub-id pub-id-type="doi">10.1007/s00412-004-0284-6</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kunick</surname><given-names>C</given-names></name><name><surname>Lauenroth</surname><given-names>K</given-names></name><name><surname>Leost</surname><given-names>M</given-names></name><name><surname>Meijer</surname><given-names>L</given-names></name><name><surname>Lemcke</surname><given-names>T</given-names></name></person-group><article-title>1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta</article-title><source>Bioorg Med Chem Lett</source><year>2004</year><volume>14</volume><fpage>413</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">14698171</pub-id><pub-id pub-id-type="doi">10.1016/j.bmcl.2003.10.062</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>R</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Berg</surname><given-names>S</given-names></name><name><surname>Hellberg</surname><given-names>S</given-names></name><name><surname>Ormo</surname><given-names>M</given-names></name><name><surname>Nilsson</surname><given-names>Y</given-names></name><name><surname>Radesater</surname><given-names>AC</given-names></name><name><surname>Jerning</surname><given-names>E</given-names></name><name><surname>Markgren</surname><given-names>PO</given-names></name><name><surname>Borgegard</surname><given-names>T</given-names></name><name><surname>Nylof</surname><given-names>M</given-names></name><name><surname>Gimenez-Cassina</surname><given-names>A</given-names></name><name><surname>Hernandez</surname><given-names>F</given-names></name><name><surname>Lucas</surname><given-names>JJ</given-names></name><name><surname>Diaz-Nido</surname><given-names>J</given-names></name><name><surname>Avila</surname><given-names>J</given-names></name></person-group><article-title>Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>45937</fpage><lpage>45945</lpage><pub-id pub-id-type="pmid">12928438</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M306268200</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarkissian</surname><given-names>M</given-names></name><name><surname>Mendez</surname><given-names>R</given-names></name><name><surname>Richter</surname><given-names>JD</given-names></name></person-group><article-title>Progesterone and insulin stimulation of CPEB-dependent polyadenylation is regulated by Aurora A and glycogen synthase kinase-3</article-title><source>Genes Dev</source><year>2004</year><volume>18</volume><fpage>48</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">14724178</pub-id><pub-id pub-id-type="doi">10.1101/gad.1136004</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roghi</surname><given-names>C</given-names></name><name><surname>Giet</surname><given-names>R</given-names></name><name><surname>Uzbekov</surname><given-names>R</given-names></name><name><surname>Morin</surname><given-names>N</given-names></name><name><surname>Chartrain</surname><given-names>I</given-names></name><name><surname>Le Guellec</surname><given-names>R</given-names></name><name><surname>Couturier</surname><given-names>A</given-names></name><name><surname>Doree</surname><given-names>M</given-names></name><name><surname>Philippe</surname><given-names>M</given-names></name><name><surname>Prigent</surname><given-names>C</given-names></name></person-group><article-title>The Xenopus protein kinase pEg2 associates with the centrosome in a cell cycle-dependent manner, binds to the spindle microtubules and is involved in bipolar mitotic spindle assembly</article-title><source>J Cell Sci</source><year>1998</year><volume>111 ( Pt 5)</volume><fpage>557</fpage><lpage>572</lpage><pub-id pub-id-type="pmid">9454730</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garrett</surname><given-names>S</given-names></name><name><surname>Auer</surname><given-names>K</given-names></name><name><surname>Compton</surname><given-names>DA</given-names></name><name><surname>Kapoor</surname><given-names>TM</given-names></name></person-group><article-title>hTPX2 is required for normal spindle morphology and centrosome integrity during vertebrate cell division</article-title><source>Curr Biol</source><year>2002</year><volume>12</volume><fpage>2055</fpage><lpage>2059</lpage><pub-id pub-id-type="pmid">12477396</pub-id><pub-id pub-id-type="doi">10.1016/S0960-9822(02)01277-0</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marumoto</surname><given-names>T</given-names></name><name><surname>Honda</surname><given-names>S</given-names></name><name><surname>Hara</surname><given-names>T</given-names></name><name><surname>Nitta</surname><given-names>M</given-names></name><name><surname>Hirota</surname><given-names>T</given-names></name><name><surname>Kohmura</surname><given-names>E</given-names></name><name><surname>Saya</surname><given-names>H</given-names></name></person-group><article-title>Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>51786</fpage><lpage>51795</lpage><pub-id pub-id-type="pmid">14523000</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M306275200</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Girdler</surname><given-names>F</given-names></name><name><surname>Gascoigne</surname><given-names>KE</given-names></name><name><surname>Eyers</surname><given-names>PA</given-names></name><name><surname>Hartmuth</surname><given-names>S</given-names></name><name><surname>Crafter</surname><given-names>C</given-names></name><name><surname>Foote</surname><given-names>KM</given-names></name><name><surname>Keen</surname><given-names>NJ</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><article-title>Validating Aurora B as an anti-cancer drug target</article-title><source>J Cell Sci</source><year>2006</year><volume>119</volume><fpage>3664</fpage><lpage>3675</lpage><pub-id pub-id-type="pmid">16912073</pub-id><pub-id pub-id-type="doi">10.1242/jcs.03145</pub-id></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dikovskaya</surname><given-names>D</given-names></name><name><surname>Schiffmann</surname><given-names>D</given-names></name><name><surname>Newton</surname><given-names>IP</given-names></name><name><surname>Oakley</surname><given-names>A</given-names></name><name><surname>Kroboth</surname><given-names>K</given-names></name><name><surname>Sansom</surname><given-names>O</given-names></name><name><surname>Jamieson</surname><given-names>TJ</given-names></name><name><surname>Meniel</surname><given-names>V</given-names></name><name><surname>Clarke</surname><given-names>A</given-names></name><name><surname>Nathke</surname><given-names>IS</given-names></name></person-group><article-title>Loss of APC induces polyploidy as a result of a combination of defects in mitosis and apoptosis</article-title><source>J Cell Biol</source><year>2007</year><volume>176</volume><fpage>183</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">17227893</pub-id><pub-id pub-id-type="doi">10.1083/jcb.200610099</pub-id></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Draviam</surname><given-names>VM</given-names></name><name><surname>Shapiro</surname><given-names>I</given-names></name><name><surname>Aldridge</surname><given-names>B</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name></person-group><article-title>Misorientation and reduced stretching of aligned sister kinetochores promote chromosome missegregation in EB1- or APC-depleted cells</article-title><source>Embo J</source><year>2006</year><volume>25</volume><fpage>2814</fpage><lpage>2827</lpage><pub-id pub-id-type="pmid">16763565</pub-id><pub-id pub-id-type="doi">10.1038/sj.emboj.7601168</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sjoblom</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Wood</surname><given-names>LD</given-names></name><name><surname>Parsons</surname><given-names>DW</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Barber</surname><given-names>TD</given-names></name><name><surname>Mandelker</surname><given-names>D</given-names></name><name><surname>Leary</surname><given-names>RJ</given-names></name><name><surname>Ptak</surname><given-names>J</given-names></name><name><surname>Silliman</surname><given-names>N</given-names></name><name><surname>Szabo</surname><given-names>S</given-names></name><name><surname>Buckhaults</surname><given-names>P</given-names></name><name><surname>Farrell</surname><given-names>C</given-names></name><name><surname>Meeh</surname><given-names>P</given-names></name><name><surname>Markowitz</surname><given-names>SD</given-names></name><name><surname>Willis</surname><given-names>J</given-names></name><name><surname>Dawson</surname><given-names>D</given-names></name><name><surname>Willson</surname><given-names>JK</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Hartigan</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Parmigiani</surname><given-names>G</given-names></name><name><surname>Park</surname><given-names>BH</given-names></name><name><surname>Bachman</surname><given-names>KE</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name></person-group><article-title>The consensus coding sequences of human breast and colorectal cancers</article-title><source>Science</source><year>2006</year><volume>314</volume><fpage>268</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">16959974</pub-id><pub-id pub-id-type="doi">10.1126/science.1133427</pub-id></citation></ref><ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoeflich</surname><given-names>KP</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Rubie</surname><given-names>EA</given-names></name><name><surname>Tsao</surname><given-names>MS</given-names></name><name><surname>Jin</surname><given-names>O</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name></person-group><article-title>Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation</article-title><source>Nature</source><year>2000</year><volume>406</volume><fpage>86</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">10894547</pub-id><pub-id pub-id-type="doi">10.1038/35017574</pub-id></citation></ref><ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>A</given-names></name><name><surname>Baines</surname><given-names>AJ</given-names></name><name><surname>Gull</surname><given-names>K</given-names></name></person-group><article-title>A high molecular mass phosphoprotein defined by a novel monoclonal antibody is closely associated with the intermicrotubule cross bridges in the Trypanosoma brucei cytoskeleton</article-title><source>J Cell Sci</source><year>1992</year><volume>103 ( Pt 3)</volume><fpage>665</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">1478963</pub-id></citation></ref><ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ditchfield</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>VL</given-names></name><name><surname>Tighe</surname><given-names>A</given-names></name><name><surname>Ellston</surname><given-names>R</given-names></name><name><surname>Haworth</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>T</given-names></name><name><surname>Mortlock</surname><given-names>A</given-names></name><name><surname>Keen</surname><given-names>N</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><article-title>Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores</article-title><source>J Cell Biol</source><year>2003</year><volume>161</volume><fpage>267</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">12719470</pub-id><pub-id pub-id-type="doi">10.1083/jcb.200208091</pub-id></citation></ref><ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Alonso</surname><given-names>M</given-names></name><name><surname>Castro</surname><given-names>A</given-names></name><name><surname>Perez</surname><given-names>C</given-names></name><name><surname>Moreno</surname><given-names>FJ</given-names></name></person-group><article-title>First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease</article-title><source>J Med Chem</source><year>2002</year><volume>45</volume><fpage>1292</fpage><lpage>1299</lpage><pub-id pub-id-type="pmid">11881998</pub-id><pub-id pub-id-type="doi">10.1021/jm011020u</pub-id></citation></ref><ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naerum</surname><given-names>L</given-names></name><name><surname>Norskov-Lauritsen</surname><given-names>L</given-names></name><name><surname>Olesen</surname><given-names>PH</given-names></name></person-group><article-title>Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors</article-title><source>Bioorg Med Chem Lett</source><year>2002</year><volume>12</volume><fpage>1525</fpage><lpage>1528</lpage><pub-id pub-id-type="pmid">12031334</pub-id><pub-id pub-id-type="doi">10.1016/S0960-894X(02)00169-5</pub-id></citation></ref><ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname><given-names>DJ</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Prouty</surname><given-names>C</given-names></name><name><surname>Conway</surname><given-names>BR</given-names></name><name><surname>Westover</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>JZ</given-names></name><name><surname>Zhang</surname><given-names>HC</given-names></name><name><surname>Maryanoff</surname><given-names>BE</given-names></name><name><surname>Murray</surname><given-names>WV</given-names></name><name><surname>Demarest</surname><given-names>KT</given-names></name><name><surname>Kuo</surname><given-names>GH</given-names></name></person-group><article-title>Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors</article-title><source>Bioorg Med Chem</source><year>2004</year><volume>12</volume><fpage>3167</fpage><lpage>3185</lpage><pub-id pub-id-type="pmid">15158785</pub-id></citation></ref></ref-list></back></article> 